US20230050684A1 - Use of potassium channel inhibitor for treating depression - Google Patents
Use of potassium channel inhibitor for treating depression Download PDFInfo
- Publication number
- US20230050684A1 US20230050684A1 US17/717,140 US202217717140A US2023050684A1 US 20230050684 A1 US20230050684 A1 US 20230050684A1 US 202217717140 A US202217717140 A US 202217717140A US 2023050684 A1 US2023050684 A1 US 2023050684A1
- Authority
- US
- United States
- Prior art keywords
- subject
- lhb
- pharmaceutical agent
- depression
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004257 Potassium Channel Human genes 0.000 title abstract description 12
- 108020001213 potassium channel Proteins 0.000 title abstract description 12
- 229940125400 channel inhibitor Drugs 0.000 title 1
- 108010074781 Kcnj10 (channel) Proteins 0.000 claims abstract description 259
- 102100021176 ATP-sensitive inward rectifier potassium channel 10 Human genes 0.000 claims abstract description 219
- 238000000034 method Methods 0.000 claims abstract description 74
- 210000002569 neuron Anatomy 0.000 claims abstract description 61
- 230000000694 effects Effects 0.000 claims abstract description 58
- 210000001753 habenula Anatomy 0.000 claims abstract description 53
- 210000001130 astrocyte Anatomy 0.000 claims abstract description 46
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 43
- 230000009172 bursting Effects 0.000 claims abstract description 37
- 239000013598 vector Substances 0.000 claims abstract description 18
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 10
- 230000002159 abnormal effect Effects 0.000 claims abstract description 8
- 239000002773 nucleotide Substances 0.000 claims abstract description 8
- 239000004055 small Interfering RNA Substances 0.000 claims description 54
- 230000002401 inhibitory effect Effects 0.000 claims description 43
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 36
- 239000003112 inhibitor Substances 0.000 claims description 29
- 239000007924 injection Substances 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 108091006146 Channels Proteins 0.000 claims description 13
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 13
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 13
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 13
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 13
- 230000002452 interceptive effect Effects 0.000 claims description 12
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 11
- 230000000295 complement effect Effects 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 9
- 150000003384 small molecules Chemical class 0.000 claims description 9
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 8
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 8
- 229960002464 fluoxetine Drugs 0.000 claims description 8
- 229960004038 fluvoxamine Drugs 0.000 claims description 8
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 8
- 229960001158 nortriptyline Drugs 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 229960002073 sertraline Drugs 0.000 claims description 8
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- 230000004075 alteration Effects 0.000 claims description 6
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims description 5
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 5
- 229960002495 buspirone Drugs 0.000 claims description 5
- 229960003955 mianserin Drugs 0.000 claims description 5
- 241000702421 Dependoparvovirus Species 0.000 claims description 4
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 4
- 229960000836 amitriptyline Drugs 0.000 claims description 4
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960003914 desipramine Drugs 0.000 claims description 4
- 229960004801 imipramine Drugs 0.000 claims description 4
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 40
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract description 7
- 230000009368 gene silencing by RNA Effects 0.000 abstract description 7
- -1 small molecule compound Chemical class 0.000 abstract description 7
- 229920002521 macromolecule Polymers 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 47
- 239000008194 pharmaceutical composition Substances 0.000 description 40
- 238000012360 testing method Methods 0.000 description 36
- 239000003814 drug Substances 0.000 description 32
- 230000001537 neural effect Effects 0.000 description 31
- 241000282414 Homo sapiens Species 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 230000036390 resting membrane potential Effects 0.000 description 19
- 230000003140 astrocytic effect Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 229930006000 Sucrose Natural products 0.000 description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 230000002018 overexpression Effects 0.000 description 14
- 239000005720 sucrose Substances 0.000 description 14
- 108020004459 Small interfering RNA Proteins 0.000 description 13
- 238000010171 animal model Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 238000010304 firing Methods 0.000 description 12
- 238000012048 forced swim test Methods 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 229910001626 barium chloride Inorganic materials 0.000 description 11
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000003542 behavioural effect Effects 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 210000005056 cell body Anatomy 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 241001123946 Gaga Species 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 230000003139 buffering effect Effects 0.000 description 6
- 229910001414 potassium ion Inorganic materials 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 5
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003197 gene knockdown Methods 0.000 description 5
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- 101000614696 Homo sapiens ATP-sensitive inward rectifier potassium channel 10 Proteins 0.000 description 4
- 108010021466 Mutant Proteins Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000000225 synapse Anatomy 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010009983 Inwardly Rectifying Potassium Channels Proteins 0.000 description 3
- 102000009855 Inwardly Rectifying Potassium Channels Human genes 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 102000008300 Mutant Proteins Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002518 glial effect Effects 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000002102 hyperpolarization Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 150000003109 potassium Chemical class 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 241000726103 Atta Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- OOFLZRMKTMLSMH-UHFFFAOYSA-N H4atta Chemical compound OC(=O)CN(CC(O)=O)CC1=CC=CC(C=2N=C(C=C(C=2)C=2C3=CC=CC=C3C=C3C=CC=CC3=2)C=2N=C(CN(CC(O)=O)CC(O)=O)C=CC=2)=N1 OOFLZRMKTMLSMH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000888419 Homo sapiens Glial fibrillary acidic protein Proteins 0.000 description 2
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 2
- 101150042598 Kcnj10 gene Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000007267 depressive like behavior Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 102000051520 human GFAP Human genes 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 238000000923 Brown–Forsythe test Methods 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 238000012312 D’Agostino & Pearson omnibus normality test Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100289687 Mus musculus Lhb gene Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000012241 membrane hyperpolarization Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000008064 spontaneous neuronal effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
Definitions
- the present disclosure relates generally to the field of disease therapy and pharmacy field, and in particular, provides a method for treating depression and pharmaceutical compositions for treating depression and the method for manufacturing it.
- Depression is a chronic mental disorder characterized by significant and persistent low mood, lack of motivation, behavioral despair, and loss of pleasure. Patients with depression may even show suicidal tendency.
- Lateral habenula (LHb) has been considered as a key brain area for studying the pathophysiology of depression in recent years. Significant elevation of lateral habenular neurons activity has been found in many animal models of depression and patient of depression.
- Astrocytes are involved in regulating the activity of neurons, the release of transmitters, and play an important role in mental diseases, including schizophrenia, epilepsy, Alzheimer's disease, and depression (Hamilton et al., 2010).
- the postmortem brain studies found that the density, morphology and function of glial cell in frontal limbic system significantly changed in major depressive disorder compared with controls (Cotter et al., 2001; Coyle et al., 2000; Rajkowska et al., 2007). Astrocyte apoptosis by chemical drugs is sufficient to cause depressive symptoms (Banasr et al., 2008).
- Antidepressant drugs can act directly on astrocytes, significantly affecting their morphology and function, which have been proposed as one of the antidepressant mechanisms (Czeh et al., 2013). These evidence suggests that in addition to neurons, glial cells also play an important role in mental disease.
- the inward rectifier-type potassium channel is a hyperpolarization-activated potassium channel, which includes 7 families, Kir1 ⁇ Kir7.
- the same kind of Kir channel can be divided into a variety of subtypes due to the existence of splicing variance.
- the Kir channel distributes in heart, kidney, nervous system and other tissues and organs.
- Kir4.1 also known as potassium voltage-gated channel subfamily J member 10, Kcnj10 is an astrocyte expressed inwardly rectifying potassium channel, mainly responsible for setting the astrocytic RMPs and buffering the excess extracellular K + in synaptic microdomains. Dysfunction of Kir4.1 will greatly affect the function of glial cells and neurons and contribute to many diseases. In mammals, both the Kir4.1 protein sequence and the coding nucleic acid sequence are conservative.
- the inventors of the present disclosure have, for the first time and unexpectedly, found that Kir4.1 present in astrocytes of the lateral habenula (also known as LHb) is a crucial regulatory factor of depression (Cui et al. 2018). With the assistance of molecular, behavioral and electrophysiological methodologies, the inventors found out that Kir4.1 expressed in astrocytes of the lateral habenula is presented in a form that closely surrounds the cells of habenula neurons. Kir4.1 regulates the extracellular potassium balance and affects the discharging characteristics of the lateral habenula neurons, which leads to over-hyperactivity of the lateral habenula, in turn affecting the phenotype of depression.
- the inventors of the present disclosure have also discovered and demonstrated various pharmaceutical agents that are capable of inhibiting, depressing, or blocking the expression level or the functionality of Kir4.1 in the lateral habenula, and have thus provided a method and a medicament (i.e. pharmaceutical composition) for treating (suppressing) depression by inhibiting the activity of Kir4.1.
- the present disclosure provides a method for treating depression in a subject substantially through the inhibition of the activity of Kir4.1, and more specifically by use of Kir4.1 inhibitors for obtaining medicaments or pharmaceutical compositions for treating depression.
- the present disclosure also provides a pharmaceutical composition comprising a pharmaceutical agent capable of inhibiting the activity of Kir4.1 for treating depression, and further provides a formulation thereof allowing for local administration in lateral habenula and for systemic administration as well.
- the pharmaceutical agent i.e. Kir4.1 inhibitor
- the pharmaceutical agent comprises a small molecule compound which upon administration in an appropriate manner, can inhibit the activity of Kir4.1 functionality.
- the pharmaceutical agent is a selective Kir4.1 inhibitor.
- a “selective Kir4.1 inhibitor” is generally referred to as a Kir4.1 inhibitor that has no inhibitory activity against other Kir proteins, or has a significantly less inhibitory activity against other Kir proteins in compassion with that against Kir4.1, for example the inhibitory activity against other Kir proteins is 50% or less, preferably 20% or less, more preferably 5% or less, than the inhibitory activity against Kir4.1.
- such Kir4.1-inhibiting small molecule compound can be a selective serotonin reuptake inhibitor (SSRIs) (e.g. fluoxetine, sertraline, and fluvoxamine, etc.) or a tricyclic antidepressants (TCAs) (e.g. nortriptyline, amitriptyline, desipramine and imipramine, etc.) which have been shown to also inhibit Kir4.1, yet with lower affinity (Ohno et al., 2007; Wang et al., 2006).
- a highly selective and specific Kir4.1 inhibitor, VU0134992 has also been reported (Kharade et al., 2018).
- These Kir4.1-inhibiting small molecule pharmaceutical agents can be administered to a subject with depression either in a local manner (i.e. direct drug delivery to the LHb of the subject) or in a systemic manner.
- the Kir4.1 inhibitor is a small interfering RNA or a precursor thereof which suppresses expression of Kir4.1.
- RNA interference induces efficient and specific degradation of homologous mRNA with double-stranded RNA (dsRNA), thereby reducing or even eliminating the expression of the target gene.
- the interfering RNA may include small interfering RNA (siRNA), short hairpin RNA (shRNA), and/or microRNA (miRNA).
- shRNA shRNA precursor
- a short hairpin RNA comprising two short inverted repeats is administered.
- siRNA sequence was cloned into a plasmid vector as a “short hairpin”. When introduced into cells, the hairpin sequence is expressed to form a “double-stranded RNA”, and the corresponding siRNA is generated by the intracellular Dicer enzyme to exert RNA interference.
- the small interfering RNA or a precursor thereof used in the present disclosure has identical or complementary sequence with the target mRNA of Kir4.1, or have at least 90% homology with the identical or complementary sequence.
- said small interfering RNA or a precursor thereof which suppresses expression of Kir4.1 can comprise one of the following sequences, which are also the target sequences in the Kir4.1 mRNA sequence:
- the above interfering RNA or its precursor targets the sequences of the corresponding mRNA fragments of the rat Kir4.1, whose sequence is set forth in SEQ ID No. 7 (i.e., the CDS region of Genebank No. NM_031602.2).
- the sequence of the interfering RNA having one of the target sequences as set forth in SEQ ID No. 1-6 is identical or complementary to the sequence of the mRNA fragments of rat Kir4.1, or has a homology of more than 90% identical thereto or complementary therewith.
- mammals e.g., human, mouse, and the like.
- the Kir4.1 inhibitor is a mutant Kir4.1 protein with diminished or totally deactivated potassium channel activity or an nucleotide sequence or nucleic acid sequence encoding said mutant Kir4.1 protein.
- a mutant protein can compete with the wide-type protein, thereby reducing the activity or the functionality of the wide-type protein.
- the mutant protein can be expressed in a target tissue or cell by administering a vector expressible in a target tissue or cell (i.e. the vector carries an expressible mutant protein gene and/or an expression factor thereof).
- the mutant Kir4.1 protein is a mutant Kir4.1 protein with one or more mutations in the channel pore region of Kir4.1.
- said mutant Kir4.1 protein can have one or more mutations at GYG corresponding to position 130-132 of the amino acid sequence of wild-type Kir4.1 protein as set forth in SEQ ID NO. 8, for example, said GYG can be mutated to be AAA.
- Kir4.1 having the amino acid sequence of SEQ ID No. 8 is Kir4.1 (NP 113790.2) of rat.
- People of ordinary skills in the art can, based on known reports (e.g., Hiroshi et al., 2010) and understanding on the conservativeness of the sequence of Kir4.1, obtain information of the channel pore region of Kir4.1 of other mammals and introduce mutations to Kir4.1 in the channel pore region thereof.
- the Kir4.1 inhibitor is a therapeutical antibody against Kir4.1, including a polyclonal antibody or a monoclonal antibody.
- Kir4.1-inhibiting biological pharmaceutical agents i.e. non-small molecule agents such as interfering macromolecules including RNAs or mutant DNAs or antibodies
- Certain compounds are known in the art for use in the treatment of depression, which include, for example, buspirone, mianserin, fluoxetine, sertraline, fluvoxamine or nortriptyline.
- buspirone for example, buspirone, mianserin, fluoxetine, sertraline, fluvoxamine or nortriptyline.
- Kir4.1 present in astrocytes of the lateral habenula plays an important role in the treatment of depression by inhibiting the abnormal firings, and particularly the abnormal burst firings, of lateral habenula neurons.
- the Kir4.1 inhibitor in one aspect of the present disclosure, in the method, the use of Kir4.1 inhibitor in obtaining a medicament, and the pharmaceutical composition for treating depression by means of inhibiting Kir4.1 as disclosed herein, does not include buspirone, mianserin, fluoxetine, sertraline, fluvoxamine or nortriptyline. Further without affecting the novelty and inventive steps of the present disclosure, in the method, the use of Kir4.1 inhibitor in obtaining a medicament, and the pharmaceutical composition for treating depression by means of inhibiting Kir4.1 as disclosed herein, said Kir4.1 inhibitor is not a selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs).
- SSRIs selective serotonin reuptake inhibitors
- TCAs tricyclic antidepressants
- depression can be referred to as lateral-azaula-mediated depression, and in more particular, may be referred to as lateral-azaula-burst-mediated depression.
- the inventors of the present application have found and demonstrated that the abnormal firing of neurons in the lateral habenula, especially the abnormal burst firing plays an important role in the generation of depression.
- the inventors of the present application have found and demonstrated that Kir4.1 is a crucial regulatory factor on burst firing, thus can be a crucial regulatory factor of depression.
- the inventors of the present application have also identified and proved different types of Kir4.1 inhibitors.
- the inventors of the present application hereby provide methods and medicaments for treating depression.
- the method, the pharmaceutical agent, or the pharmaceutical composition provided by the present disclosure are particularly suitable for use in the depression patients to whom the above-described anti-depression methods and drug are ineffective.
- the method and the pharmaceutical agent or medicament for treating depression are configured for use in lateral habenula locally (i.e. configured to be locally administered to the lateral habenula).
- lateral habenula locally
- the administration of a medicine locally in the lateral habenula is a limiting technical feature to a method and a pharmaceutical agent for treating depression.
- the medicament or pharmaceutical composition has a dosage form for local administration to the lateral habenula.
- the action of the medicament can be limited to the target tissue by local administration, for example by formulating the medicament as a dosage form that can be administered locally to the lateral habenula by cannulation.
- the drug is formulated in a dosage form having a sustained release after being administered or delivered into the tissue.
- the above medicaments can also be formulated in the form of tissue-specific targeted drug delivery systems.
- a small molecule compound or a biologically active molecule capable of specifically binding to a protein expressed in the lateral habenula can be used to link with an antibody or fragments thereof which binds to cells of the lateral habenula to form a complex molecule capable of recognizing and binding to lateral habenula.
- the Kir4.1 inhibitor in the pharmaceutical composition for treating depression, is a small interfering RNA or a precursor thereof which suppresses expression of Kir4.1.
- the small interfering RNA or a precursor thereof used in the present disclosure has identical or complementary sequence with the target mRNA of Kir4.1, or have at least 90% homology with the identical or complementary sequence.
- said small interfering RNA or a precursor thereof which is capable of suppressing expression of Kir4.1 has one of the following sequences:
- said Kir4.1 inhibitor does not include buspirone, mianserin, fluoxetine, sertraline, fluvoxamine or nortriptyline, and the like.
- said Kir4.1 inhibitor is not a selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs).
- the pharmaceutical composition for treating depression are configured for local administration in lateral habenula.
- said pharmaceutical composition can be in a formulation that is locally administered in lateral habenula.
- said Kir4.1 inhibitor can include a selective serotonin reuptake inhibitor (such as buspirone, mianserin, fluoxetine, sertraline, fluvoxamine) or tricyclic antidepressants (such as nortriptyline).
- a pharmaceutical composition for treating depression in a subject especially in a mammal subject (e.g. a rat, a mouse, or a human).
- the pharmaceutical composition comprises a therapeutically effective amount of a pharmaceutical agent (i.e. the active component in the pharmaceutical composition).
- the pharmaceutical agent is capable of, upon administration to the subject, suppressing an expression, interfering with a function, or inhibiting an activity, of an astroglial potassium channel in a lateral habenula (LHb) of the subject such that bursting activity of neurons in the lateral habenula (LHb) of the subject is suppressed.
- the pharmaceutical agent if in a therapeutically effective amount, is capable of suppressing an expression, interfering with a function, or inhibiting an activity, of Kir4.1 in a lateral habenula (LHb) of the subject in a selective manner.
- selective manner is referred to as a situation that only Kir4.1 is inhibited or suppressed by the pharmaceutical composition without noticeable inhibitory effects on other inward rectifier potassium channel family members.
- the pharmaceutical agent is capable of suppressing an expression or interfering with a function of Kir4.1 in astrocytes in the lateral habenula (LHb) of the subject to thereby inhibit the activity of the astroglial potassium channel in the subject.
- the pharmaceutical agent can comprise a recombinant vector, such as a recombinant viral vector (e.g. recombinant adeno-associated virus (AAV) vector), that is configured to express in the astrocytes in the lateral habenula of the subject biological molecules capable of suppressing the expression, or block the function, of Kir4.1.
- a recombinant viral vector e.g. recombinant adeno-associated virus (AAV) vector
- AAV adeno-associated virus
- the biological molecules comprise RNA molecules that are capable of suppressing or silencing the expression of Kir4.1 through RNA interference (RNAi), and as such, the RNA molecules can comprise at least one of a short hairpin RNA (shRNA) molecule, a small interfering RNA (siRNA) molecule, a micro-RNA (miRNA) molecule, or an antisense RNA molecule.
- shRNA short hairpin RNA
- siRNA small interfering RNA
- miRNA micro-RNA
- antisense RNA molecule an antisense RNA molecule.
- the RNA molecules comprise a shRNA molecule, which comprises two complementary sequences, and one of the two complementary sequences has a nucleotide sequence that is substantially identical to a sequence as set forth in any one of SEQ ID NOS. 1-6.
- the one of the two complementary sequences has a nucleotide sequence that is identical to the sequence as set forth in SEQ ID NO. 2.
- a shRNA can be universally used to suppress or silent the expression of Kir4.1 to thereby be employed in the pharmaceutical composition for treating depression in mammals like human, since the target sequence of this particular shRNA in the Kir4.1 mRNA sequence is 100% identical across rat, mouse and human.
- the recombinant vector includes a promoter that is operably connected to, and configured to drive an astrocyte-specific expression of, a functional sequence to thereby generate the biological molecules.
- a functional sequence can be the above mentioned Kir4.1-targeting shRNA, or a dominant negative mutant Kir4.1, which will also be described below.
- the promoter can optionally be a human GFAP (gfaABC1D) promoter.
- the biological molecules comprise polypeptide molecules that are capable of inhibiting the function of Kir4.1, such as a mutant Kir4.1 protein that is capable of interfering with the function of Kir4.1 in a dominant negative manner.
- the mutant Kir4.1 protein comprises a sequence alteration at a channel core region of a Kir4.1 protein of the subject.
- the sequence alteration can be preferably at a GYG segment corresponding to position 130-132 of the Kir4.1 protein as set forth in any one of SEQ ID NOS. 8, 16 or 18 (i.e. corresponding to rat, mouse and human Kir4.1 protein sequences respectively).
- the sequence alteration comprises a GYG-to-AAA point mutation.
- the pharmaceutical agent comprises a small molecule agent capable of inhibiting the activity of the astroglial potassium channel in the astrocytes in the lateral habenula of the subject.
- the small molecule agent can be a Kir4.1-inhibiting selective serotonin reuptake inhibitor (SSRIs) (e.g. fluoxetine, sertraline, and fluvoxamine, etc.) or a Kir4.1-inhibiting tricyclic antidepressants (TCAs) (e.g. nortriptyline, amitriptyline, desipramine and imipramine, etc.), and more preferably, can be a highly selective Kir4.1 inhibitor VU0134992.
- SSRIs selective serotonin reuptake inhibitor
- TCAs tricyclic antidepressants
- the present disclosure further provides a method for treating depression in a subject.
- the method comprises: administering to the subject a pharmaceutical composition according to any one of the embodiments as described above.
- the administering the virus particles to the subject can be through an injection or an inhalation, or another practical administration method.
- the pharmaceutical agent in the pharmaceutical composition comprises a small molecule agent capable of inhibiting the activity of the astroglial potassium channel in the astrocytes in the lateral habenula of the subject.
- the step of administering to the subject a pharmaceutical composition comprises:
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising a virus particle of the invention in a pharmaceutically-acceptable carrier or other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.
- the carrier will typically be a liquid.
- the carrier may be either solid or liquid, such as sterile, pyrogen-free water or sterile pyrogen-free phosphate-buffered saline solution.
- the carrier will be respirable, and will preferably be in solid or liquid particulate form.
- water that contains the additives usual for injection solutions, such as stabilizing agents, salts or saline, and/or buffers.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a cell in which an AAV provirus is integrated into the genome in a pharmaceutically-acceptable carrier or other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.
- pharmaceutically acceptable it is meant a material that is not biologically or otherwise undesirable, e.g., the material may be administered to a subject without causing any undesirable biological effects.
- a pharmaceutical composition may be used, for example, in transfection of a cell ex vivo or in administering a viral particle or cell directly to a subject.
- the present disclosure also provides an animal model of depression, which can be a rat or a mouse.
- the animal model of depression provided herein shows symptoms of depression, and has overexpressed Kir4.1 in the lateral habenula.
- the present disclosure further provides a method for screening potential substances for treating depression using the animal model of depression as described above.
- the screening method comprises the steps of:
- test substance is a potential substance that can be used to treat depression.
- said method further comprises one or more if the following steps:
- test substance in comparison with the negative control group, if the expression level of Kir4.1 is significantly decreased, and/or the Kir4.1 channel activity is significantly decreased, it indicates that the test substance is a potential substance that can be used to treat depression.
- the method of screening for a potential substance for treating depression further comprises one or more of the following steps:
- the potential substances screened in the previous step are administered to animal models to observe their effects on the symptoms of depression.
- test substances are potential substances for the treatment of depression.
- the present disclosure also provides a method of diagnosing depression, comprising detecting the expression of Kir4.1 in the lateral habenula of the patient.
- the method of diagnosing depression comprises: detecting an increase in expression of Kir4.1 in the lateral habenula of a subject (such as a human patient).
- the method of diagnosing depression comprises: comparing the expression of Kir4.1 in lateral habenula of the patient at different timings (for example, at different stages of depression, or before or after treatment), or comparing the expression of Kir4.1 in the lateral habenular of a normal subject to that in a general or a specific population. If the expression of Kir4.1 is significantly increased, the subject is diagnoses to have depression.
- expression of Kir4.1 can be detected by any methods known in the art for detecting protein (expression) in a sample.
- the methods can identify the presence or absence of Kir4.1.
- the methods can also quantitatively detect the amount of expression of Kir4.1.
- Methods for detecting a protein (expression) in a sample which can be used in the present disclosure include immunoassay.
- immunoassay For example, ELISA or Western blotting carried out with an antibody that specifically recognizes Kir4.1, in which the antibodies can be monoclonal or polyclonal antibodies.
- Methods for detecting a protein (expression) in a sample can be used in the present disclosure further comprises detecting the presence or amount of mRNA of Kir4.1, for example, detecting the amount of mRNA of Kir4.1 or a fragment thereof in the sample by RT-PCR.
- the test sample is from the lateral habenular of the subject.
- the test sample is from an ex vivo sample.
- detection of the expression of Kir4.1 can also be performed by in vivo observation and detection of the amount of Kir4.1 of the lateral habenular of the subject.
- the test includes imaging the lateral habenular of the patient, for example PET imaging.
- the positron emission tomography (PET) scan of the lateral habenular is carried out by intravenous injection of positron emission radionuclide tracer which recognizes and displays Kir4.1, and followed by a positron emission tomography (PET) scan.
- PET positron emission tomography
- the subject to whom the method is applied and the pharmaceutical composition is administered as described in the present disclosure can be a mammal, including a human or a non-human primate such as a monkey.
- the mammal can be other animals such as rats, mice, rabbits, pigs, dogs, and the like.
- the mammal can be a domestic animal such as a cat or a dog.
- the term “pharmaceutical agent”, “therapeutic agent”, or “agent”, or alike, that is capable of inhibiting Kir4.1 can be referred to as an agent which can decrease or eliminate Kir4.1 channel activity, and the Kir4.1 channel activity is referred to as a functionality of Kir4.1 that allows potassium ions to pass through cell membrane. Kir4.1 regulates the potassium ion concentration of the external fluid around the nerve cells and transports excess extracellular potassium ions to buffer the extracellular environment and control the resting membrane potential level, thereby affecting the physiological activity of the nervous system.
- a pharmaceutical agent capable of inhibiting Kir4.1 may comprise a compound, a composition, or a mixture that can decrease or eliminate the Kir4.1 channel activity, and may optionally comprise an agent or a reagent that is used in the method for inhibiting Kir4.1 activity (including a surgical method), and the like.
- the pharmaceutical agent capable of inhibiting Kir4.1 may be an agent which can affect the protein level and/or the protein activity of Kir4.1, so as to affect the Kir4.1 channel activity.
- the pharmaceutical agent as such can be of an entity of a small molecule compound or composition, or can be of an entity of an active macromolecule such as a protein or a nucleic acid.
- the pharmaceutical agent can be an antagonist such as an antibody that directly binds to and negatively modulates the functionality of, Kir4.1, or can be a nucleic acid that directly affects the expression level of Kir4.1, or optionally can further be a protein/nucleic acid that indirectly modulates the expression level and/or functionality of Kir4.1.
- antagonists such as an antibody that directly binds to and negatively modulates the functionality of, Kir4.1
- nucleic acid that directly affects the expression level of Kir4.1
- optionally can further be a protein/nucleic acid that indirectly modulates the expression level and/or functionality of Kir4.1.
- protein agents or nucleic acid agents can be delivered to a target tissue or cell by techniques well known in the art, for example, in conjunction with a suitable expression vector.
- Kir4.1 is also known as potassium voltage-gated channel subfamily J member 10 (Kcnj10).
- Kir4.1 is a member of inward rectifier potassium channel.
- Kir4.1 in neurogliocytes allows potassium ions to pass through cell membrane.
- Kir4.1 regulates the potassium ion concentration of the external fluid around the nerve cells and transports excess extracellular potassium ions to buffer the extracellular environment and control the resting membrane potential level, thus affecting the physiological activity of the nervous system.
- the amino acid sequence of Kir 4.1 and the nucleotide sequence encoding it are both very conservative.
- Gene encoding human Kir4.1 NP_002232
- KCNJ10 Ensembl: ENSG00000177807
- Gene encoding rat Kir4.1 (NP_113790) is KCNJ110 (Ensembl: ENSMUSG00000044708).
- treatment can be interpreted to include a process or an outcome thereof that ameliorates, palliates, decreases or prevents the symptoms associated with depression; a process or an outcome thereof that improves the symptoms associated with depression; a process or an outcome thereof that normalizes body functions in diseases or disorders that result in impairment of the specific body functions; or a process or an outcome thereof that elicits an improvement in one or more of the clinically measured parameters of the disease.
- a treatment objective is to prevent or slow down (i.e. lessen) an undesired physiological condition, disorder or disease, or to obtain a beneficial or desired result.
- the result can be, e.g., medical, physiological, clinical, physical therapy, occupational therapy, and subjective to a health care worker or to a patient; or can be interpreted in the field as a parameter for “quality of life” or for “activity of daily living”.
- the “beneficial or desired result” can comprise, but are not limited to, alleviation of symptoms; diminution/diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration or palliation of the condition, disorder or disease; and remission (partially or totally), whether detectable or undetectable; or enhancement or improvement of the condition, disorder or disease.
- treatment includes eliciting a clinically significant response without excessive levels of side effects.
- treatment also includes prolonged survival as compared to expected survival if not receiving treatment.
- treatment is referred to as the administration of a medicine, or the application of a medical procedure, to a patient.
- treatment can comprise prevention or curing of a weakness or a disease of a patient, or can comprise amelioration of the clinical condition of the patient, including a reduced duration or severity of an illness, an improved quality of life of the patient, or a prolonged survival of the patient.
- burst or “burst firing”, as referred to throughout the disclosure, is defined as a firing pattern in neurons that has two or more spontaneous bursts, or spikes of plateau potentials (short as spikes hereafter) in each time of firing (i.e. each burst).
- inhibiting burst firing is referred to as inhibiting a level of neuronal burst firing, which can include: reducing at least one of a number of burst firing cells in the lateral habenula, a ratio of burst firing cells among neurons in the lateral habenula, a probability of the burst firing, a frequency of the burst firing, an amplitude of the burst firing, a duration of the burst firing, or a spike number per burst.
- neuronal firing is referred to as a neuronal firing pattern with only one spike in each burst.
- FIGS. 1 A- 1 F show that Kir4.1 is upregulated in the LHb of the animal models of depression.
- FIGS. 1 A and 1 B Western blot analysis showing upregulation of Kir4.1 protein in membrane fraction of habenula of cLH ( FIG. 1 A ) and LPS-induced depression rat models ( FIG. 1 B ). Tubulin is used as loading control.
- FIGS. 1 C and 1 D I-V plot and bar graph showing Ba 2+ -sensitive current in cLH rats and their wild type controls at the age of P60-90 ( FIG. 1 C ) and P30 ( FIG. 1 D ).
- FIGS. 1 E and 1 F Age-dependent learned helpless ( FIG. 1 E ) and forced swim ( FIG.
- FIGS. 2 A- 2 D show that Kir4.1 is expressed on astrocytic processes tightly wrapping around neuronal soma.
- FIG. 2 A Immunohistochemistry signals of Kir4.1 envelope neuronal soma as indicated by white arrows.
- FIG. 2 B The pan-soma Kir4.1 signals remain intact in LHb of Kir4.1-floxed mice injected with AAV2/1-CaMKII-EGFP-Cre, but are eliminated when injected with AAV2/5-GFAP-EGFP-Cre, (GFAP: human astrocyte-specific GFAP promoter, gfaABC1D).
- FIG. 2 C Immunogold electron microscopy of Kir4.1. Red arrows indicate gold signals surrounding a neuronal soma.
- FIGS. 3 A- 3 B show that Kir4.1 is expressed in astrocytic processes of LHb and astrocytic soma of hippocampus.
- FIGS. 3 A and 3 B Kir4.1 co-immunostaining with neuronal marker (NeuN) or astrocytic marker (S100b and GFAP) in LHb ( FIG. 3 A ) or hippocampus ( FIG. 3 B ). Bottom two panels are staining with the same kir4.1 antibody pre-incubated with the antigen peptide, demonstrating Kir4.1 antibody.
- FIGS. 4 A- 4 K show that extracellular potassium is highly correlated with the activity pattern and tightly control by astrocytic kir4.1.
- FIGS. 4 A- 4 C Changes of neuronal RMPs caused by BaCl 2 (100 ⁇ M) in different neuronal types.
- FIGS. 4 D- 4 E Correlation between BaCl 2 -sensitive membrane potential and tonic firing frequency ( FIG. 4 D ), inner burst firing frequency ( FIG. 4 E ) and burst total spike frequency.
- FIGS. 4 G- 4 H Representative trace ( FIG. 4 G ) and bar graph ( FIG. 4 H ) shows BaCl 2 effect onto bursting neurons.
- FIG. 4 G Representative trace
- FIG. 4 H shows BaCl 2 effect onto bursting neurons.
- FIGS. 4 J and 4 K Lowering Kout to half decreases neuronal RMPs ( FIG. 4 J ) and increases the bursting population in neurons ( FIG. 4 K ).
- FIGS. 5 A- 5 I show that overexpression of astrocytic kir4.1 increases neuronal bursts in LHb and causes depressive-like phenotypes.
- FIG. 5 A Schematics of AAV vectors engineered to overexpress a control construct and Kir4.1 under GFAP.
- FIG. 5 B Illustration of bilateral viral injection of AAV-GFAP-Kir4.1 in mouse LHb (stained with antibody against GFP and Hoechst).
- FIG. 5 C Experimental paradigm for electrophysiology and behavioral testing.
- FIGS. 5 D- 5 F Astrocytic overexpression of Kir4.1 decreases RMPs of both astrocytes ( FIG. 5 D ) and neurons ( FIG. 5 E ) and increases the bursting population in neurons ( FIG.
- FIG. 5 F Histogram of inter-spike intervals (ISI, ms) distribution.
- the ISIs of LHb neurons in astrocytic Kir4.1-overexpressed mice exhibited a clear bimodal distribution with an extra sharp and condensed cluster of high frequency events centred around 40 ms, indicating a significant weight increase of burst firings.
- FIGS. 5 H and 5 I Behavioral effects of expressing various viral constructs in LHb in forced swim test (FST) ( FIG. 5 H ) and sucrose preference test (SPT) ( FIG. 5 I ). Data are means ⁇ SEM. **P ⁇ 0.01, ***P ⁇ 0.001, ****P ⁇ 0.0001; n.s., not significant.
- FIGS. 6 A- 6 L show that loss of function of Kir4.1 in LHb decreases neuronal bursting and rescues depressive-like phenotypes.
- FIG. 6 A Schematics of the AAV vector engineered to overexpress shRNA or dominant negative form of Kir4.1. H1, human H1 promoter. CAG: The CMV early enhancer/chicken beta actin promoter.
- FIG. 6 B Western blot and quantification showing efficient knock-down of Kir4.1 by shRNA in HEK293T cells.
- FIGS. 6 C- 6 H Electrophysiological characterization in LHb of AAV-Kir4.1-shRNA and AAV-ctrl-shRNA injected rats.
- FIG. 6 D Experimental paradigm for behavioral testing of cLH rats infected by virus.
- FIG. 6 E I-V plots showing a shift of reverse potential from ⁇ 72 mV to ⁇ 40 mV in astrocytes infected by AAV-Kir4.1-shRNA.
- FIGS. 6 F and 6 G AAV-Kir4.1-shRNA caused more depolarized RMP in astrocytes ( FIG. 6 F ) and neurons in the viral infected region ( FIG. 6 G ).
- FIG. 6 H AAV-Kir4.1-shRNA abolished neuronal bursting.
- FIG. 6 I- 6 L Behavioral effects of expressing various viral constructs in the LHb of cLH rats in forced swim ( FIG. 6 I ), learned helpless ( FIGS. 6 J and 6 K ) and sucrose preference ( FIG. 6 L ) tests. *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001, ****P ⁇ 0.0001, n.s., not significant.
- FIG. 7 shows characterization of Kir4.1 loss-of-function constructs.
- Flag-tagged-Kir4.1 plasmid pAAV-CMV-betaGlobin-Kir4.1-eGFP-3Flag
- pAAV-vector expressing 6 different shRNAs see Methods
- shRNA of luciferase the negative control
- Kir4.1-shRNA-5 was chosen for viral package.
- FIGS. 8 A- 8 B show that overexpression of Kir4.1 or Kir4.1-shRNA in LHb does not affect locomotion in open field test.
- FIG. 8 A Overexpression of Kir4.in LHb does not affect locomotion activities.
- FIG. 8 B Overexpression of Kir41-shRNA in LHb does not affect locomotion activities. Data are means ⁇ SEM. n.s., not significant.
- FIGS. 9 A- 9 C show the nucleotide sequence comparison between human, mouse and rat Kir4.1 mRNAs.
- FIG. 9 D shows the amino acid sequence comparison between human, mouse and rat Kir4.1 proteins.
- FIG. 9 E shows the sequence alignment results between the target sequence correspond to each of the shRNA No. 1-6 and the human Kir4.1 mRNA sequence.
- mice Male Wistar rats (12 weeks) and Sprague Dawley rats (3-4 weeks or 12 weeks) were purchased from Shanghai SLAC Laboratory Animal Co. The cLH rats were introduced from Malinow's lab in Cold Spring Harbor of USA, and screened by learned helpless test for breeding as previously described (Schulz et al., 2010). Male cLH rats (3-4 weeks or 12 weeks) were used. Male adult (7-8 weeks of age) C57BL/6 mice (SLAC) were used for virus injection experiments. Animals were group-housed two/cage for rats and four/cage for mice under a 12-h light-dark cycle (light on from 7 a.m. to 7 p.m.). Animals were housed in stable conditions with food and water ad libitum. All animal studies and experimental procedures were approved by the Animal Care and Use Committee of the animal facility at Zhejiang University.
- AAV5-gfaABC1D-GFP-CreMut (titer: 4.74 ⁇ 10 12 v.g./ml) was ordered and prepared by Taitool Bioscience of China.
- AAV2/1-CamKII-HI-eGFP-Cre were purchase from University of Pennsylvania Vector core, Upenn, USA (Cat #: AV-1-PV2521). All viral vectors were aliquoted and stored at ⁇ 80° C. until use.
- AAV2/5-gfaABC1D-EGFP-Kir4.1 was prepared, for which pZac2.1 gfaABC1D-eGFP-Kir4.1 plasmid (AddGene, Plasmid #52874) and the AAV virus (Taitool Bioscience of China, titer: 9.19 ⁇ 10 12 v.g./ml) was used.
- the package and preparation of the Kir4.1 overexpression viral deliver system was ordered and prepared from Taitool Bioscience of China.
- a blank control, AAV-GFAP::GFP which expressed GFP but not Kir4.1 was also ordered and prepared from Taitool Bioscience of China.
- Kir4.1 mutation construct and viral deliver system namely AAV5-gfaABC1D-dnKir4.1-2A-eGFP, titer: 4.15 ⁇ 10 13 v.g./ml
- GYG at position 130-132 are mutated to be AAA was ordered and prepared from Taitool Bioscience of China.
- sequence as set forth in SEQ ID No. 20 is the reverse complimentary of the sequence as set forth in SEQ ID No. 19, and the sequence as set forth in SEQ ID No. 20 consists substantially of a sequence (TTTGCAAGGAAGGTTCCGG, as set forth in SEQ ID No. 12), which is substantially the reverse complimentary of the sequence as set forth in SEQ ID No. 4, plus a “C” at its 3′ end.
- TTTGCAAGGAAGGTTCCGG as set forth in SEQ ID No. 12
- the knocking down efficiency was tested by Western blot of Kir4.1 from HEK293TN cells which were co-transfected with Flag-tagged-Kir4.1 plasmid (pAAV-CMV-betaGlobin-Kir4.1-eGFP-3Flag) and each of the six shRNA plasmids.
- LPS-induced depression model The LPS-induced depression model was conducted as previously described (Adzic et al., 2015). Adult (3 months) Wistar male rats were used for the experiments. LPS (Sigma, L-2880) dissolved in sterile 0.9% saline was intraperitoneally injected into Wistar rats, at a dosage of 0.5 mg/kg. This dosage was used to stimulate a subclinical infection without inducing obvious inflammation and other apparent impairment in the animals. Saline or LPS was injected between 09:30 and 10:30 a.m. daily for 7 days. The forced swim test was performed 24 hours after the last injection. The habenular tissue was dissected 24 hours after the behavioral test.
- Virus injection was performed using a mircoinjection needle with a pressure microinjector (Picospritzer III, Parker, USA) delivering virus at a slow rate of 0.1 ul/min. After the injection was completed, two minutes were allowed to pass and leaving it for an additional 10 minutes before the needle was then slowly withdrawn completely. After surgery, mice recovered from anesthesia under a heat pad.
- mice or rats were used in behavioral or electrophysiological studies. All the injection sites will be checked by immunostaining after the behavioral experiments. Only mice with correct injection site will be counted into the behavioral statistics.
- the rabbit anti-Kir4.1 extracellular peptide antibody was pre-adsorbed with the Kir4.1 antigen by mixing at the weight ratio of 1:2 for 24 h. Slices were counterstained with Hoechst in the final incubation step to check the injection site. Fluorescent image acquisition was performed with an Olympus Fluoview FV1000 confocal microscope and a Nikon A1confocal microscope.
- the habenular membrane fraction and whole protein was extracted as previously described 11 .
- Animals were anesthetized using 10% chloral hydrate, and habenular tissue was quickly dissected from the brain and homogenized in lysis buffer (320 mM sucrose, 4 mM HEPES pH7.4, 1 mM MgCl 2 and 0.5 mM CaCl 2 , 5 mM NaF, 1 mM Na 3 VO 4 , EDTA-free, Protease Inhibitor cocktail tablets (Roche)) on ice.
- lysis buffer 320 mM sucrose, 4 mM HEPES pH7.4, 1 mM MgCl 2 and 0.5 mM CaCl 2 , 5 mM NaF, 1 mM Na 3 VO 4 , EDTA-free, Protease Inhibitor cocktail tablets (Roche)
- the lysis buffer used for extracting the total protein of HEK293TN cell contained 50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS and Protease Inhibitor cocktail tablets (Roche). After protein concentration measurement by BCA assay, 10 ⁇ 20 ⁇ g proteins for each lane was separated on a 10% SDS-PAGE gel and transferred for western blot analysis. Anti-Kir4.1 (1:1000, Alomone labs), anti-GFAP (1:1000, Sigma) and anti-tubulin (1:5000, Bio-Rad) antibodies were used. High sensitive ECL reagent was used (GE Healthcare). All the bands were analyzed with Quantity one or Image J.
- Rats (P25-30 or P60-90) and mice (P90) were anesthetized with isoflurane and 10% chloral hydrate, and then perfused with 20 ml ice-cold ACSF (oxygenated with 95% O 2 +5% CO 2 ) containing (mM): 125 NaCl, 2.5 KCl, 25 NaHCO 3 , 1.25 NaH 2 PO 4 , 1 MgCl 2 , 2.5 CaCl 2 ) and 25 Glucose, with 1 mM pyruvate added.
- the brain was removed as quickly as possible after decapitation and put into chilled and oxygenated ACSF.
- Coronal slices containing habenular (350 ⁇ m- and 300 ⁇ m-thickness for rats and mice, respectively) were sectioned in cold ACSF by a Leica2000 vibratome and then transferred to ASCF at 32° C. for incubation and recovery. ACSF was continuously gassed with 95% 02 and 5% CO 2 . Slices were allowed to recover for at least 1 hour before recording.
- TTX (1 ⁇ M, Sigma) and BaCl 2 (100 ⁇ M, Sigma) effect onto neuronal RMP
- baselines of RMP were recorded for at least for 3 min. Drug were then perfused, the arriving of the drug was precisely indicated with a bubble that pre-added before the transition from normal ACSF to drug added ACSF.
- TTX acts on LHb neuron as quickly as several minutes while BaCl 2 takes more 10 min to affect neuronal RMP.
- the drug effect of TTX and BaCl 2 onto neuronal RMP at the time point of 5 min and 15 min were then tested respectively.
- LHT Learned helpless test
- Male juvenile (P30) or adult (P90) cLH rats were tested in a lever-pressing task to evaluate the learned helpless (LH) phenotype 11 .
- a cue-light-illuminated lever in the shock chamber was presented, which can terminate the shock when rats pressed the lever.
- 15 escapable shocks (0.8 mA) were delivered with a 24 s inter-shock interval were given. Each shock lasted up to 60 s unless the rat pressed the lever to terminate the shock.
- LH learned helplessness
- NLH non-learned helplessness
- FST Forced swim test
- Animals were individually placed in a cylinder (12 cm diameter, 25 cm height for mice; 20 cm diameter, 50 cm height for rats) of water (23-25° C.) and swam for 6 min under normal light. Water depth was set to prevent animals from touching the bottom by tails and hind limbs. Animal behaviors were videotaped from the side.
- the immobility time during the last 4 min test was counted offline by an observer blind of the animal treatments. Immobility was defined as time when animals remained floating or motionless with only movements necessary for keeping balance in the water.
- an additional pre-test was conducted 24 h before the test, during which rats were individually placed in a cylinder of water with conditions described above for 15 min.
- sucrose preference test (SPT). Animals were single housed and habituated with two bottles of water for 2 days, followed by two bottles of 2% sucrose for 2 days. Animals were then water deprived for 24 h and then exposed to one bottle of 2% sucrose and one bottle of water for 2 h in the dark phase. Bottle positions were switched after 1 h. Total consumption of each fluid was measured and sucrose preference was defined as the ratio of sucrose consumption divided by total consumptions of water and sucrose.
- Kir4.1 is a principal component of the glial Kir channel and is largely responsible for mediating the K+ conductance and setting the RMP of astrocytes.
- whole-cell patch clamp was performed onto the astrocytes in brain slices made from the LHb of cLH or SD rats.
- Astrocytes were distinguished from neurons by their small (5-10 ⁇ M) oval shaped somata and electrophysiological features including a relatively hyperpolarized RMP ( ⁇ 74 ⁇ 1 mV), a low input resistance Rin (47 ⁇ 6 M ⁇ ), a linear I-V relationship and an absence of action potentials in response to depolarizing current injections ( FIG. 1 C ).
- Ba 2+ (BaCl 2 , 100 ⁇ M) was then bath applied, which selectively blocks Kir channels at sub-mM concentrations, to isolate Kir4.1 current.
- the Ba 2+ -sensitive currents displayed a reversal potential close to Ek ( ⁇ 90 mV) ( FIGS. 1 E and 1 F ), indicating it represents the K+ conductance. It was found that Ba 2+ -sensitive currents in LHb astrocytes were almost doubled in cLH rats, compared with SD controls, at the age of P60-90 ( FIG. 1 C ). Interestingly, the increase of Kir4.1 current was not obvious at P30 ( FIG. 1 D ).
- Kir4.1 As an inwardly rectifying K + channel, Kir4.1 has been strongly implicated in buffering excess extracellular K + in tripartite synapses. Conventional model of K+ buffering suggests Kir4.1 to be highly expressed in astrocytic endfeet surrounding synapses. Surprisingly, with immunohistochemistry co-labeling, Kir4.1 staining in LHb appeared to overlap with the neuronal marker NeuN at low magnification (20 ⁇ , FIG. 3 A ), although in the same brain slice Kir4.1 staining patterns in hippocampus were typical astrocytic-looking ( FIG. 3 B ). However, higher magnification imaging with single layer scanning (0.76 ⁇ m per layer) revealed that Kir4.1 staining enveloped NeuN signals ( FIG. 2 A ).
- Kir4.1 indeed locates within astrocytes but not neurons in LHb
- kir4.1 was separately knocked out in either neurons or astrocytes by injecting AAV virus expressing the cre recombinase under either the neuronal promoter CaMKII or glial promoter GFAP (gfaABC1D) into Kir4.1-floxed mice by using AAV5-gfaABC1D-GFP-CreMut (titer: 4.74 ⁇ 10 12 v.g./ml), which was provided as mentioned in Example 1.
- the neural-surrounding staining of Kir4.1 remained intact with neuronal knock-out, but was completely eliminated with astrocytic knock-out ( FIG. 2 B ).
- Example 5 Enhanced Capacity of Extracellular K + Clearance Due to Kir4.1 Overexpression May Underlie the Neuronal Hyperpolarization Required for Burst Initiation
- a Kir4.1 overexpression system AAV2/5-gfaABC1D-EGFP-Kir4.1 (namely “AAV-Kir4.1” or “AAV-GFAP::Kir4.1”) was prepared and assayed, which uses adeno-associated viruses of the 2/5 serotype (AAV2/5) that preferentially target astrocytes as the vector, together with the human GFAP (gfaABC1D) promoter for the expression.
- the Kir4.1 overexpression system GFP-tagged Kir4.1 channels (AAV-GFAP::Kir4.1) was prepared as described in Example 1, while AAV-GFAP::GFP which expressed GFP but not Kir4.1 was used as a control ( FIG. 5 A ).
- FIG. 5 B Whole-cell recordings were made from either astrocytes or neurons surrounding the viral-transfected astrocytes in coronal LHb slices.
- the RMPs of both astrocytes and neurons were more hyperpolarized ( FIGS. 5 D and 5 E ) and the percentage of bursting neurons were significantly higher ( FIG. 5 F ) in mice infected with AAV-GFAP::Kir4.1 than with AAV-GFAP::GFP.
- mice with AAV-GFAP::Kir4.1 infection in the LHb displayed severe depressive-like behaviors ( FIGS. 5 C- 5 I ), including increased immobile duration and decreased latency to immobility in FST ( FIG. 5 H ), and decreased sucrose preference in the sucrose preference test (SPT, FIG. 5 I ).
- FIG. 6 E In astrocytes infected with the AAV-Kir4.1-shRNA vector, it was found that a dramatic change of I-V relation ( FIG. 6 E ) and a 32 mV depolarization compared with neighboring non-infected astrocytes and 41 mV depolarization compared with ctrl-shRNA-GFP+ astrocytes ( FIG. 6 F ).
- the RMPs did not differ from neighboring non-infected neurons (because neurons do not express Kir4.1 endogenously, FIG. 6 G ).
- RMPs of LHb neurons from AAV-Kir4.1-shRNA-infected brain slices were overall more depolarized than RMPs of those from AAV-luciferase-shRNA-infected rats ( ⁇ 43 ⁇ 2 mV vs. ⁇ 53 ⁇ 2.7 Mv, FIG. 6 G ), suggesting that knock-down of Kir4.1 in astrocytes had a global impact on RMPs of neighboring neurons.
- bursting activity in LHb of cLH rats were completely eliminated by AAV-Kir4.1-shRNA viral infection (from 29% to 0%, FIG. 6 H ).
- Kir4.1 a dominant-negative form of Kir4.1, dnKir4.1, containing a GYG to AAA point mutation at the channel pore which blocks K + channels was also tested.
- the preparation of the Kir4.1 mutation construct and viral deliver system (namely AAV-dnKir4.1, or AAV5-gfaABC1D-dnKir4.1-2A-eGFP) was prepared as described in Example 1.
- Infection of AAV-dnKir4.1 caused similarly strong anti-depression effects in cLH rats ( FIGS. 6 I- 6 L ): reducing the immobility time and increasing latency to immobility in FST ( FIG. 6 I ), increasing bar pressing number in the LHT ( FIGS. 6 J and 6 K ), and increasing the sucrose preference score in SPT ( FIG. 6 L ).
- Kir4.1 shall play a similarly crucial role in the lateral habenula (LHb) in the pathogenesis and maintenance of depression.
- shRNA-2 As such, among the 6 shRNAs that have been utilized for suppressing expression of rat Kir4.1, at least the shRNA-2, likely the shRNA-1, 6 and 5, and potentially shRNA-4 as well, can be utilized to suppress the expression of human Kir4.1, and thus can serve as a component of a pharmaceutical agent capable of inhibiting the activity of the astroglial potassium channel Kir4.1 in a human subject with depression to suppress the bursting activity of neurons in a lateral habenula of the subject for treatment of the disease.
- Kir4.1 protein i.e. dnKir4.1
- dnKir4.1 dominant negative mutant form of Kir4.1 protein
- dnKir4.1 containing a GYG-to-AAA point mutation corresponding to position 130-132 of the amino acid sequence of wild-type Kir4.1 protein of rat Kir4.1 (as set forth in SEQ ID NO. 8)
- the three-amino-acid sequence is strictly conserved within the 88-amino acid context region at positions 101-188 of all of the human, mouse and rat Kir4.1 proteins (as respectively set forth in SEQ ID NOS. 18, 16 and 8, see FIG.
- tissue-specific overexpression of such a mutant protein in the LHb of a human subject is expected to also interfere with the normal functionality of Kir4.1 in a dominant negative manner, and consequently, the bursting activity in the LHb of the human subject can be eliminated, thereby realizing an effective treatment of depression in the human subject.
- the dnKir4.1 can similarly be used as a pharmaceutical agent capable of inhibiting the activity of the astroglial potassium channel Kir4.1 in a human subject with depression to suppress the bursting activity of neurons in a lateral habenula of the subject for treatment of the disease.
- the vectors that have been utilized for the astrocyte-specific expression of shRNAs or dnKir4.1 in the rat studies as described above, such as AAV-GFAP, and esp. the AAV2/5 shall also be able to realize a similar astrocyte-specific expression of shRNAs (e.g. shRNA-2) and dnKir4.1 to be able to exert the therapeutic effects.
- the present disclosure for the first time and unexpectedly find that burst in neurons of the lateral habenula has an important role in the cause of depression, and identify key factors affecting the burst in the lateral habenula, including that the activation of NMDA receptors is the sufficient and necessary condition for inducing burst in the lateral habenula, and that burst in the lateral habenula need the participation of neuron membrane hyperpolarization and T-type low voltage activate calcium channel.
- the inventors provide a method and medicament for diagnosing and treating (inhibiting) depression by inhibiting burst in lateral habenula, especially method and medicament for rapidly treating (inhibiting) depression.
- the temperature unit “degrees” refers to Celsius degrees, namely ° C.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
Abstract
The present disclosure provides a method for treating depression using a therapeutically effective amount of a pharmaceutical agent. The pharmaceutical agent can inhibit an activity of an astroglial potassium channel, and especially inhibit the functionality of Kir4.1, in astrocytes in the lateral habenula of a subject so that the abnormal burst firings of neurons in the lateral habenula of the subject can be suppressed. The pharmaceutical agent can include a vector expressing a target nucleotide sequence in the astrocytes in the lateral habenula, whose expression is configured to suppress Kir4.1 expression by RNA interference, or to block Kir4.1 functionality by a dominant negative effect of a mutant Kir4.1 protein. The pharmaceutical agent can alternatively comprise a small molecule compound, or an active macromolecule such as an anti-Kir4.1 antibody, that can directly inhibit the astroglial potassium channel activity.
Description
- The present application is a divisional application of U.S. patent application Ser. No. 16/679,197 filed Nov. 9, 2019, which is a continuation of International Patent Application No. PCT/CN2018/086021 filed May 8, 2018, which claims priority to Chinese Patent Application No. 201710322245.X, filed May 9, 2017. These related patent applications are hereby incorporated into the present application by reference in their entirety.
- The content of the electronically submitted sequence listing, with the file name SeqList-KChannInhibitor-Updated-ST25.txt, size 17,421 bytes, and date of creation Jan. 15, 2020, filed herewith, is incorporated herein by reference in its entirety.
- The present disclosure relates generally to the field of disease therapy and pharmacy field, and in particular, provides a method for treating depression and pharmaceutical compositions for treating depression and the method for manufacturing it.
- Depression is a chronic mental disorder characterized by significant and persistent low mood, lack of motivation, behavioral despair, and loss of pleasure. Patients with depression may even show suicidal tendency.
- Lateral habenula (LHb) has been considered as a key brain area for studying the pathophysiology of depression in recent years. Significant elevation of lateral habenular neurons activity has been found in many animal models of depression and patient of depression.
- Abnormal neuron activities are mainly attributed to the dysfunction of synaptic transmission and changes in their physiological characteristics and the surrounding of neurons. Astrocytes are involved in regulating the activity of neurons, the release of transmitters, and play an important role in mental diseases, including schizophrenia, epilepsy, Alzheimer's disease, and depression (Hamilton et al., 2010). The postmortem brain studies found that the density, morphology and function of glial cell in frontal limbic system significantly changed in major depressive disorder compared with controls (Cotter et al., 2001; Coyle et al., 2000; Rajkowska et al., 2007). Astrocyte apoptosis by chemical drugs is sufficient to cause depressive symptoms (Banasr et al., 2008). Antidepressant drugs can act directly on astrocytes, significantly affecting their morphology and function, which have been proposed as one of the antidepressant mechanisms (Czeh et al., 2013). These evidence suggests that in addition to neurons, glial cells also play an important role in mental disease.
- The inward rectifier-type potassium channel (Kir) is a hyperpolarization-activated potassium channel, which includes 7 families, Kir1˜Kir7. The same kind of Kir channel can be divided into a variety of subtypes due to the existence of splicing variance. The Kir channel distributes in heart, kidney, nervous system and other tissues and organs. Kir4.1 (also known as potassium voltage-gated channel
subfamily J member 10, Kcnj10) is an astrocyte expressed inwardly rectifying potassium channel, mainly responsible for setting the astrocytic RMPs and buffering the excess extracellular K+ in synaptic microdomains. Dysfunction of Kir4.1 will greatly affect the function of glial cells and neurons and contribute to many diseases. In mammals, both the Kir4.1 protein sequence and the coding nucleic acid sequence are conservative. - There are some existing antidepressants in the field, but these drugs usually take effect after a long period of time. Almost all known existing antidepressants in the field typically take a week to several weeks to be capable of exerting antidepressant effects. For example, the commonly used 5-HT reuptake inhibitors (SSRI) are usually effective in 2-3 weeks; 5-HT and serotonin and norepinephrine reuptake inhibitors are usually only effective after 1 week. Moreover, the pathological mechanism leading to depression has not been fully recognized. There is a need in the art for new methods and drugs for treating depression, which have a faster onset rate or a safer effective dosage.
- The inventors of the present disclosure have, for the first time and unexpectedly, found that Kir4.1 present in astrocytes of the lateral habenula (also known as LHb) is a crucial regulatory factor of depression (Cui et al. 2018). With the assistance of molecular, behavioral and electrophysiological methodologies, the inventors found out that Kir4.1 expressed in astrocytes of the lateral habenula is presented in a form that closely surrounds the cells of habenula neurons. Kir4.1 regulates the extracellular potassium balance and affects the discharging characteristics of the lateral habenula neurons, which leads to over-hyperactivity of the lateral habenula, in turn affecting the phenotype of depression. The inventors of the present disclosure have also discovered and demonstrated various pharmaceutical agents that are capable of inhibiting, depressing, or blocking the expression level or the functionality of Kir4.1 in the lateral habenula, and have thus provided a method and a medicament (i.e. pharmaceutical composition) for treating (suppressing) depression by inhibiting the activity of Kir4.1.
- In particular, based on the above discoveries, the present disclosure provides a method for treating depression in a subject substantially through the inhibition of the activity of Kir4.1, and more specifically by use of Kir4.1 inhibitors for obtaining medicaments or pharmaceutical compositions for treating depression. The present disclosure also provides a pharmaceutical composition comprising a pharmaceutical agent capable of inhibiting the activity of Kir4.1 for treating depression, and further provides a formulation thereof allowing for local administration in lateral habenula and for systemic administration as well.
- According to some embodiments of the disclosure, the pharmaceutical agent (i.e. Kir4.1 inhibitor) comprises a small molecule compound which upon administration in an appropriate manner, can inhibit the activity of Kir4.1 functionality. According to some preferred embodiments of the disclosure, the pharmaceutical agent is a selective Kir4.1 inhibitor. Herein, a “selective Kir4.1 inhibitor” is generally referred to as a Kir4.1 inhibitor that has no inhibitory activity against other Kir proteins, or has a significantly less inhibitory activity against other Kir proteins in compassion with that against Kir4.1, for example the inhibitory activity against other Kir proteins is 50% or less, preferably 20% or less, more preferably 5% or less, than the inhibitory activity against Kir4.1.
- Herein optionally, such Kir4.1-inhibiting small molecule compound can be a selective serotonin reuptake inhibitor (SSRIs) (e.g. fluoxetine, sertraline, and fluvoxamine, etc.) or a tricyclic antidepressants (TCAs) (e.g. nortriptyline, amitriptyline, desipramine and imipramine, etc.) which have been shown to also inhibit Kir4.1, yet with lower affinity (Ohno et al., 2007; Wang et al., 2006). A highly selective and specific Kir4.1 inhibitor, VU0134992, has also been reported (Kharade et al., 2018). These Kir4.1-inhibiting small molecule pharmaceutical agents can be administered to a subject with depression either in a local manner (i.e. direct drug delivery to the LHb of the subject) or in a systemic manner.
- According to some other embodiments of the present disclosure, the Kir4.1 inhibitor is a small interfering RNA or a precursor thereof which suppresses expression of Kir4.1. RNA interference (RNAi) induces efficient and specific degradation of homologous mRNA with double-stranded RNA (dsRNA), thereby reducing or even eliminating the expression of the target gene. In the present disclosure, the interfering RNA may include small interfering RNA (siRNA), short hairpin RNA (shRNA), and/or microRNA (miRNA). One way to administer interfering RNA in vivo is to administer a shRNA (siRNA precursor), such as a short hairpin RNA comprising two short inverted repeats. The siRNA sequence was cloned into a plasmid vector as a “short hairpin”. When introduced into cells, the hairpin sequence is expressed to form a “double-stranded RNA”, and the corresponding siRNA is generated by the intracellular Dicer enzyme to exert RNA interference.
- According to different embodiments of the present disclosure, the small interfering RNA or a precursor thereof used in the present disclosure has identical or complementary sequence with the target mRNA of Kir4.1, or have at least 90% homology with the identical or complementary sequence. For example, according to some embodiments of the present disclosure, said small interfering RNA or a precursor thereof which suppresses expression of Kir4.1 can comprise one of the following sequences, which are also the target sequences in the Kir4.1 mRNA sequence:
-
(SEQ ID No. 1) 5′-GGACGACCTTCATTGACAT-3′; (SEQ ID No. 2) 5′-GCTAC AAGCTTCTGCTCTTCT-3′; (SEQ ID No. 3) 5′-GCTCTTCTCGCC AACCTTTAC-3′; (SEQ ID No. 4) 5′-CCGGAACCTTCCTTGCAAA-3′; (SEQ ID No. 5) 5′-GCGTAAGAGTCTCCTC ATTGG-3′; or (SEQ ID No. 6) 5′-GCCCTT AGTGTGCGC ATT A-3′. - The above interfering RNA or its precursor targets the sequences of the corresponding mRNA fragments of the rat Kir4.1, whose sequence is set forth in SEQ ID No. 7 (i.e., the CDS region of Genebank No. NM_031602.2). In other words, the sequence of the interfering RNA having one of the target sequences as set forth in SEQ ID No. 1-6 is identical or complementary to the sequence of the mRNA fragments of rat Kir4.1, or has a homology of more than 90% identical thereto or complementary therewith. People of ordinary skills in the field will understand and be able to obtain fragments of an interfering RNA sequence of the Kir4.1 correspondingly in other mammals (e.g., human, mouse, and the like).
- According to some embodiments of the present disclosure, the Kir4.1 inhibitor is a mutant Kir4.1 protein with diminished or totally deactivated potassium channel activity or an nucleotide sequence or nucleic acid sequence encoding said mutant Kir4.1 protein. A mutant protein can compete with the wide-type protein, thereby reducing the activity or the functionality of the wide-type protein. The mutant protein can be expressed in a target tissue or cell by administering a vector expressible in a target tissue or cell (i.e. the vector carries an expressible mutant protein gene and/or an expression factor thereof). According to some more specific embodiments of the disclosure, the mutant Kir4.1 protein is a mutant Kir4.1 protein with one or more mutations in the channel pore region of Kir4.1. Optionally, said mutant Kir4.1 protein can have one or more mutations at GYG corresponding to position 130-132 of the amino acid sequence of wild-type Kir4.1 protein as set forth in SEQ ID NO. 8, for example, said GYG can be mutated to be AAA. Kir4.1 having the amino acid sequence of SEQ ID No. 8 is Kir4.1 (NP 113790.2) of rat. People of ordinary skills in the art can, based on known reports (e.g., Hiroshi et al., 2010) and understanding on the conservativeness of the sequence of Kir4.1, obtain information of the channel pore region of Kir4.1 of other mammals and introduce mutations to Kir4.1 in the channel pore region thereof.
- According to some embodiments of the present disclosure, the Kir4.1 inhibitor is a therapeutical antibody against Kir4.1, including a polyclonal antibody or a monoclonal antibody.
- These above Kir4.1-inhibiting biological pharmaceutical agents (i.e. non-small molecule agents such as interfering macromolecules including RNAs or mutant DNAs or antibodies) can be administered to a subject with depression either in a local manner (i.e. direct delivery to the LHb of the subject) or in a systemic manner.
- Certain compounds are known in the art for use in the treatment of depression, which include, for example, buspirone, mianserin, fluoxetine, sertraline, fluvoxamine or nortriptyline. However, in these reports, the anti-depression mechanisms that have been discovered or presumed are completely different from the mechanism discovered by the present disclosure, that is, Kir4.1 present in astrocytes of the lateral habenula plays an important role in the treatment of depression by inhibiting the abnormal firings, and particularly the abnormal burst firings, of lateral habenula neurons. Without affecting the novelty and inventive steps of the present disclosure, in one aspect of the present disclosure, in the method, the use of Kir4.1 inhibitor in obtaining a medicament, and the pharmaceutical composition for treating depression by means of inhibiting Kir4.1 as disclosed herein, the Kir4.1 inhibitor does not include buspirone, mianserin, fluoxetine, sertraline, fluvoxamine or nortriptyline. Further without affecting the novelty and inventive steps of the present disclosure, in the method, the use of Kir4.1 inhibitor in obtaining a medicament, and the pharmaceutical composition for treating depression by means of inhibiting Kir4.1 as disclosed herein, said Kir4.1 inhibitor is not a selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs).
- In the present disclosure, the term “depression” can be referred to as lateral-habenula-mediated depression, and in more particular, may be referred to as lateral-habenula-burst-mediated depression. The inventors of the present application have found and demonstrated that the abnormal firing of neurons in the lateral habenula, especially the abnormal burst firing plays an important role in the generation of depression. The inventors of the present application have found and demonstrated that Kir4.1 is a crucial regulatory factor on burst firing, thus can be a crucial regulatory factor of depression. The inventors of the present application have also identified and proved different types of Kir4.1 inhibitors. The inventors of the present application hereby provide methods and medicaments for treating depression. This is a pathological mechanism containing the target tissue in the brain and the molecular targets that currently known mechanisms and drugs have failed to target. Accordingly, the method, the pharmaceutical agent, or the pharmaceutical composition provided by the present disclosure are particularly suitable for use in the depression patients to whom the above-described anti-depression methods and drug are ineffective.
- According to some embodiments of the present disclosure, the method and the pharmaceutical agent or medicament for treating depression are configured for use in lateral habenula locally (i.e. configured to be locally administered to the lateral habenula). For methods and medicaments/agents used on nerve tissues, particularly the nerve tissues in the brain, such as on the lateral habenula, it is beneficial to limit the effects of the drug/medicament/pharmaceutical agent to the target tissue. The administration of a medicine locally in the lateral habenula is a limiting technical feature to a method and a pharmaceutical agent for treating depression. In any method or pharmaceutical agent or medicament for LHb, whether the method or drug can take effects in LHb shall be considered, including whether the drug can reach LHb, and whether the effective concentration can be achieved in LHb, etc. According to some embodiments of the present disclosure, the medicament or pharmaceutical composition has a dosage form for local administration to the lateral habenula. The action of the medicament can be limited to the target tissue by local administration, for example by formulating the medicament as a dosage form that can be administered locally to the lateral habenula by cannulation. In another example, the drug is formulated in a dosage form having a sustained release after being administered or delivered into the tissue. The above medicaments can also be formulated in the form of tissue-specific targeted drug delivery systems. For example, a small molecule compound or a biologically active molecule (nucleic acid such as a protein-encoding DNA or mRNA molecule, or a protein such as an antibody, etc.) capable of specifically binding to a protein expressed in the lateral habenula can be used to link with an antibody or fragments thereof which binds to cells of the lateral habenula to form a complex molecule capable of recognizing and binding to lateral habenula.
- According to some embodiments of the present disclosure, in the method for treating depression by inhibiting Kir4.1 in the lateral habenula and the use of a Kir4.1 inhibitor as a pharmaceutical agent for treating depression which is locally administered in the lateral habenula, said Kir4.1 inhibitor can comprise a Kir4.1-inhibiting small molecule compound or a pharmaceutically acceptable formula thereof. Herein the Kir4.1-inhibiting small molecule compound or the a pharmaceutically acceptable formula thereof can be a selective serotonin reuptake inhibitor capable of inhibiting Kir4.1 activity (e.g. fluoxetine, sertraline, and fluvoxamine, etc.) or a tricyclic antidepressant capable of inhibiting Kir4.1 activity (e.g. nortriptyline, amitriptyline, desipramine and imipramine, etc.), or can be a selective Kir4.1 inhibitor (such as VU0134992).
- In another aspect, the present disclosure also provides a pharmaceutical composition for treating depression, comprising a therapeutically effective amount of Kir4.1 inhibitor, which is substantially the pharmaceutical agent in the pharmaceutical composition, wherein said Kir4.1 inhibitor is as defined and described above.
- According to some embodiments of the present disclosure, in the pharmaceutical composition for treating depression, the Kir4.1 inhibitor is a small interfering RNA or a precursor thereof which suppresses expression of Kir4.1. In one aspect of the present disclosure, the small interfering RNA or a precursor thereof used in the present disclosure has identical or complementary sequence with the target mRNA of Kir4.1, or have at least 90% homology with the identical or complementary sequence. For example, according to some embodiments, said small interfering RNA or a precursor thereof which is capable of suppressing expression of Kir4.1 has one of the following sequences:
-
(SEQ ID No. 1) 5′-GGACGACCTTCATTGACAT-3′; (SEQ ID No. 2) 5′-GCTACAAGCTTCTGCTCTTCT-3′; (SEQ ID No. 3) 5′-GCTCTTCTCGCCAACCTTTAC-3′; (SEQ ID No. 4) 5′-CCGGAACCTTCCTTGCAAA-3′; (SEQ ID No. 5) 5′-GCGTAAGAGTCTCCTCATTGG-3′; or (SEQ ID No. 6) 5′-GCCCTTAGTGTGCGCATTA-3′. - According to some embodiments of the present disclosure, in the pharmaceutical composition for treating depression, the Kir4.1 inhibitor can be a mutant Kir4.1 protein with diminished or deactivated potassium channel activity, or can be an encoding nucleotide sequence thereof. Optionally, the mutant Kir4.1 protein can be a mutant Kir4.1 protein with a mutation in the channel pore region of Kir4.1. Furthermore, said mutant Kir4.1 protein can have a mutation in GYG at positions 130-132 of the amino acid sequence as set forth in SEQ ID NO. 8. For example, said GYG can be mutated to be AAA.
- According to some embodiments of the present disclosure, in the pharmaceutical composition for treating depression, the Kir4.1 inhibitor can be a specific antibody against Kir4.1, including a polyclonal antibody or a monoclonal antibody.
- Without affecting the novelty and inventive steps of the present disclosure, according to some embodiments of the present disclosure, in the pharmaceutical composition for treating depression, said Kir4.1 inhibitor does not include buspirone, mianserin, fluoxetine, sertraline, fluvoxamine or nortriptyline, and the like. Without affecting the novelty and inventive steps of the present disclosure, according to some embodiments of the present disclosure, in the pharmaceutical composition for treating depression, said Kir4.1 inhibitor is not a selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs).
- The pharmaceutical composition for treating depression provided by the present disclosure are particularly suitable for treating depression patients to whom the other anti-depression methods and drug are ineffective.
- According to some embodiments of the present disclosure, the pharmaceutical composition for treating depression are configured for local administration in lateral habenula. For example, said pharmaceutical composition can be in a formulation that is locally administered in lateral habenula. For these locally administered pharmaceutical composition for treating depression disclosed herein, said Kir4.1 inhibitor can include a selective serotonin reuptake inhibitor (such as buspirone, mianserin, fluoxetine, sertraline, fluvoxamine) or tricyclic antidepressants (such as nortriptyline).
- In summary of the above, in a first aspect of the present disclosure, a pharmaceutical composition for treating depression in a subject, especially in a mammal subject (e.g. a rat, a mouse, or a human), is provided. The pharmaceutical composition comprises a therapeutically effective amount of a pharmaceutical agent (i.e. the active component in the pharmaceutical composition). The pharmaceutical agent is capable of, upon administration to the subject, suppressing an expression, interfering with a function, or inhibiting an activity, of an astroglial potassium channel in a lateral habenula (LHb) of the subject such that bursting activity of neurons in the lateral habenula (LHb) of the subject is suppressed.
- According to some embodiments of the pharmaceutical composition, the pharmaceutical agent, if in a therapeutically effective amount, is capable of suppressing an expression, interfering with a function, or inhibiting an activity, of Kir4.1 in a lateral habenula (LHb) of the subject in a selective manner. Herein “selective manner” is referred to as a situation that only Kir4.1 is inhibited or suppressed by the pharmaceutical composition without noticeable inhibitory effects on other inward rectifier potassium channel family members.
- According to some embodiments of the pharmaceutical composition disclosed herein, the pharmaceutical agent is capable of suppressing an expression or interfering with a function of Kir4.1 in astrocytes in the lateral habenula (LHb) of the subject to thereby inhibit the activity of the astroglial potassium channel in the subject.
- Optionally, the pharmaceutical agent can comprise a recombinant vector, such as a recombinant viral vector (e.g. recombinant adeno-associated virus (AAV) vector), that is configured to express in the astrocytes in the lateral habenula of the subject biological molecules capable of suppressing the expression, or block the function, of Kir4.1.
- According to some embodiments, the biological molecules comprise RNA molecules that are capable of suppressing or silencing the expression of Kir4.1 through RNA interference (RNAi), and as such, the RNA molecules can comprise at least one of a short hairpin RNA (shRNA) molecule, a small interfering RNA (siRNA) molecule, a micro-RNA (miRNA) molecule, or an antisense RNA molecule.
- According to certain specific embodiments, the RNA molecules comprise a shRNA molecule, which comprises two complementary sequences, and one of the two complementary sequences has a nucleotide sequence that is substantially identical to a sequence as set forth in any one of SEQ ID NOS. 1-6.
- Preferably, the one of the two complementary sequences has a nucleotide sequence that is identical to the sequence as set forth in SEQ ID NO. 2. Such a shRNA can be universally used to suppress or silent the expression of Kir4.1 to thereby be employed in the pharmaceutical composition for treating depression in mammals like human, since the target sequence of this particular shRNA in the Kir4.1 mRNA sequence is 100% identical across rat, mouse and human.
- Preferably in the pharmaceutical composition, the recombinant vector can be a recombinant viral vector capable of preferentially or specifically targeting the astrocytes of the subject, such as based on an adeno-associated virus (AAV) of 2/5 serotype (AAV2/5).
- According to some embodiments, the recombinant vector includes a promoter that is operably connected to, and configured to drive an astrocyte-specific expression of, a functional sequence to thereby generate the biological molecules. Herein the functional sequence can be the above mentioned Kir4.1-targeting shRNA, or a dominant negative mutant Kir4.1, which will also be described below. The promoter can optionally be a human GFAP (gfaABC1D) promoter.
- According to some embodiments of the pharmaceutical composition, the biological molecules comprise polypeptide molecules that are capable of inhibiting the function of Kir4.1, such as a mutant Kir4.1 protein that is capable of interfering with the function of Kir4.1 in a dominant negative manner. Herein, optionally the mutant Kir4.1 protein comprises a sequence alteration at a channel core region of a Kir4.1 protein of the subject. The sequence alteration can be preferably at a GYG segment corresponding to position 130-132 of the Kir4.1 protein as set forth in any one of SEQ ID NOS. 8, 16 or 18 (i.e. corresponding to rat, mouse and human Kir4.1 protein sequences respectively). According to one specific embodiment, the sequence alteration comprises a GYG-to-AAA point mutation.
- According to some embodiments of the pharmaceutical composition, the pharmaceutical agent comprises a small molecule agent capable of inhibiting the activity of the astroglial potassium channel in the astrocytes in the lateral habenula of the subject. Herein optionally, the small molecule agent can be a Kir4.1-inhibiting selective serotonin reuptake inhibitor (SSRIs) (e.g. fluoxetine, sertraline, and fluvoxamine, etc.) or a Kir4.1-inhibiting tricyclic antidepressants (TCAs) (e.g. nortriptyline, amitriptyline, desipramine and imipramine, etc.), and more preferably, can be a highly selective Kir4.1 inhibitor VU0134992.
- In a second aspect, the present disclosure further provides a method for treating depression in a subject. The method comprises: administering to the subject a pharmaceutical composition according to any one of the embodiments as described above.
- According to some embodiments, the pharmaceutical agent in the pharmaceutical composition comprises a recombinant viral vector configured to express in the astrocytes in the lateral habenula of the subject biological molecules capable of suppressing the expression, or block the function, of Kir4.1, and as such, the step of administering to the subject a pharmaceutical composition comprises:
- obtaining virus particles carrying the recombinant viral vector; and
- the virus particles to the subject.
- Optionally, the administering the virus particles to the subject can be through an injection or an inhalation, or another practical administration method.
- According to some other embodiments, the pharmaceutical agent in the pharmaceutical composition comprises a small molecule agent capable of inhibiting the activity of the astroglial potassium channel in the astrocytes in the lateral habenula of the subject. As such, the step of administering to the subject a pharmaceutical composition comprises:
- administering the pharmaceutical composition in a systemic manner; or
- administering the pharmaceutical composition locally to the lateral habenula of the subject.
- In particular embodiments, the present disclosure provides a pharmaceutical composition comprising a virus particle of the invention in a pharmaceutically-acceptable carrier or other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc. For injection, the carrier will typically be a liquid. For other methods of administration, the carrier may be either solid or liquid, such as sterile, pyrogen-free water or sterile pyrogen-free phosphate-buffered saline solution. For inhalation administration, the carrier will be respirable, and will preferably be in solid or liquid particulate form. As an injection medium, it is preferred to use water that contains the additives usual for injection solutions, such as stabilizing agents, salts or saline, and/or buffers.
- In other embodiments, the present invention provides a pharmaceutical composition comprising a cell in which an AAV provirus is integrated into the genome in a pharmaceutically-acceptable carrier or other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.
- Herein, by “pharmaceutically acceptable” it is meant a material that is not biologically or otherwise undesirable, e.g., the material may be administered to a subject without causing any undesirable biological effects. Thus, such a pharmaceutical composition may be used, for example, in transfection of a cell ex vivo or in administering a viral particle or cell directly to a subject.
- In yet another aspect, the present disclosure also provides an animal model of depression, which can be a rat or a mouse. The animal model of depression provided herein shows symptoms of depression, and has overexpressed Kir4.1 in the lateral habenula.
- In yet another aspect, the present disclosure further provides a method for screening potential substances for treating depression using the animal model of depression as described above. The screening method comprises the steps of:
- (1) adding a test substance to be screened to an in vitro testing system;
- (2) checking an expression level and/or an activity of Kir4.1 in an in vitro testing system in the testing group; comparing it with the control group.
- Wherein, if the symptoms associated with depression in the animal model of depression are significantly improved, it indicates that the test substance is a potential substance that can be used to treat depression.
- In yet another aspect of the present disclosure, said method further comprises one or more if the following steps:
- further testing the effect of the test substance on the burst in neuron; and/or
- administering said test substance to an animal model of depression and observing how it affects the symptoms associated with depression.
- Wherein, in comparison with the negative control group, if the expression level of Kir4.1 is significantly decreased, and/or the Kir4.1 channel activity is significantly decreased, it indicates that the test substance is a potential substance that can be used to treat depression.
- In still another aspect of the disclosure, the method of screening for a potential substance for treating depression further comprises one or more of the following steps:
- the potential substances screened in the previous step are further tested for their effects on the burst in neurons; and/or
- the potential substances screened in the previous step are administered to animal models to observe their effects on the symptoms of depression.
- When testing the effect on the burst in neurons, if the ratio of burst in neurons in the test group to which the test substance was added or administered is significantly lower than that of the negative control group (or the blank control group), it means that test substances are potential substances for the treatment of depression.
- In yet another aspect, the present disclosure also provides a method of diagnosing depression, comprising detecting the expression of Kir4.1 in the lateral habenula of the patient. According to some embodiments, the method of diagnosing depression comprises: detecting an increase in expression of Kir4.1 in the lateral habenula of a subject (such as a human patient). According to some more specific embodiments, the method of diagnosing depression comprises: comparing the expression of Kir4.1 in lateral habenula of the patient at different timings (for example, at different stages of depression, or before or after treatment), or comparing the expression of Kir4.1 in the lateral habenular of a normal subject to that in a general or a specific population. If the expression of Kir4.1 is significantly increased, the subject is diagnoses to have depression.
- In one aspect of the disclosure, expression of Kir4.1 can be detected by any methods known in the art for detecting protein (expression) in a sample. The methods can identify the presence or absence of Kir4.1. The methods can also quantitatively detect the amount of expression of Kir4.1.
- Methods for detecting a protein (expression) in a sample which can be used in the present disclosure include immunoassay. For example, ELISA or Western blotting carried out with an antibody that specifically recognizes Kir4.1, in which the antibodies can be monoclonal or polyclonal antibodies.
- Methods for detecting a protein (expression) in a sample can be used in the present disclosure further comprises detecting the presence or amount of mRNA of Kir4.1, for example, detecting the amount of mRNA of Kir4.1 or a fragment thereof in the sample by RT-PCR.
- According to some embodiments of the disclosure, the test sample is from the lateral habenular of the subject. Optionally, the test sample is from an ex vivo sample. Optionally, detection of the expression of Kir4.1 can also be performed by in vivo observation and detection of the amount of Kir4.1 of the lateral habenular of the subject. For example, the test includes imaging the lateral habenular of the patient, for example PET imaging. The positron emission tomography (PET) scan of the lateral habenular is carried out by intravenous injection of positron emission radionuclide tracer which recognizes and displays Kir4.1, and followed by a positron emission tomography (PET) scan.
- Throughout the disclosure, the following terms are defined.
- The subject to whom the method is applied and the pharmaceutical composition is administered as described in the present disclosure can be a mammal, including a human or a non-human primate such as a monkey. The mammal can be other animals such as rats, mice, rabbits, pigs, dogs, and the like. The mammal can be a domestic animal such as a cat or a dog.
- Herein, the term “pharmaceutical agent”, “therapeutic agent”, or “agent”, or alike, that is capable of inhibiting Kir4.1 can be referred to as an agent which can decrease or eliminate Kir4.1 channel activity, and the Kir4.1 channel activity is referred to as a functionality of Kir4.1 that allows potassium ions to pass through cell membrane. Kir4.1 regulates the potassium ion concentration of the external fluid around the nerve cells and transports excess extracellular potassium ions to buffer the extracellular environment and control the resting membrane potential level, thereby affecting the physiological activity of the nervous system. Notably, a pharmaceutical agent capable of inhibiting Kir4.1 may comprise a compound, a composition, or a mixture that can decrease or eliminate the Kir4.1 channel activity, and may optionally comprise an agent or a reagent that is used in the method for inhibiting Kir4.1 activity (including a surgical method), and the like. Further optionally, the pharmaceutical agent capable of inhibiting Kir4.1 may be an agent which can affect the protein level and/or the protein activity of Kir4.1, so as to affect the Kir4.1 channel activity. The pharmaceutical agent as such can be of an entity of a small molecule compound or composition, or can be of an entity of an active macromolecule such as a protein or a nucleic acid. For example, the pharmaceutical agent can be an antagonist such as an antibody that directly binds to and negatively modulates the functionality of, Kir4.1, or can be a nucleic acid that directly affects the expression level of Kir4.1, or optionally can further be a protein/nucleic acid that indirectly modulates the expression level and/or functionality of Kir4.1. These protein agents or nucleic acid agents can be delivered to a target tissue or cell by techniques well known in the art, for example, in conjunction with a suitable expression vector.
- Throughout the disclosure, the term “Kir4.1”, or “inward rectifier potassium channel Kir4.1”, is also known as potassium voltage-gated channel subfamily J member 10 (Kcnj10). Kir4.1 is a member of inward rectifier potassium channel. Kir4.1 in neurogliocytes allows potassium ions to pass through cell membrane. Kir4.1 regulates the potassium ion concentration of the external fluid around the nerve cells and transports excess extracellular potassium ions to buffer the extracellular environment and control the resting membrane potential level, thus affecting the physiological activity of the nervous system. In mammals, the amino acid sequence of Kir 4.1 and the nucleotide sequence encoding it are both very conservative. Gene encoding human Kir4.1 (NP_002232) is KCNJ10 (Ensembl: ENSG00000177807). Gene encoding rat Kir4.1 (NP_113790) is KCNJ110 (Ensembl: ENSMUSG00000044708).
- As used herein and throughout the disclosure, the term “treatment” can be interpreted to include a process or an outcome thereof that ameliorates, palliates, decreases or prevents the symptoms associated with depression; a process or an outcome thereof that improves the symptoms associated with depression; a process or an outcome thereof that normalizes body functions in diseases or disorders that result in impairment of the specific body functions; or a process or an outcome thereof that elicits an improvement in one or more of the clinically measured parameters of the disease. In one embodiment, a treatment objective is to prevent or slow down (i.e. lessen) an undesired physiological condition, disorder or disease, or to obtain a beneficial or desired result. Herein the result can be, e.g., medical, physiological, clinical, physical therapy, occupational therapy, and subjective to a health care worker or to a patient; or can be interpreted in the field as a parameter for “quality of life” or for “activity of daily living”. For the purposes of this disclosure, the “beneficial or desired result” can comprise, but are not limited to, alleviation of symptoms; diminution/diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration or palliation of the condition, disorder or disease; and remission (partially or totally), whether detectable or undetectable; or enhancement or improvement of the condition, disorder or disease. In one embodiment, treatment includes eliciting a clinically significant response without excessive levels of side effects. In another embodiment, treatment also includes prolonged survival as compared to expected survival if not receiving treatment. In yet another embodiment, treatment is referred to as the administration of a medicine, or the application of a medical procedure, to a patient. As used herein, treatment can comprise prevention or curing of a weakness or a disease of a patient, or can comprise amelioration of the clinical condition of the patient, including a reduced duration or severity of an illness, an improved quality of life of the patient, or a prolonged survival of the patient.
- The term “burst”, or “burst firing”, as referred to throughout the disclosure, is defined as a firing pattern in neurons that has two or more spontaneous bursts, or spikes of plateau potentials (short as spikes hereafter) in each time of firing (i.e. each burst).
- The term “inhibiting burst firing”, “inhibition of burst firing”, “inhibiting burst”, “inhibition of burst”, or alike, is referred to as inhibiting a level of neuronal burst firing, which can include: reducing at least one of a number of burst firing cells in the lateral habenula, a ratio of burst firing cells among neurons in the lateral habenula, a probability of the burst firing, a frequency of the burst firing, an amplitude of the burst firing, a duration of the burst firing, or a spike number per burst.
- The term “tonic firing” is referred to as a neuronal firing pattern with only one spike in each burst.
-
FIGS. 1A-1F show that Kir4.1 is upregulated in the LHb of the animal models of depression.FIGS. 1A and 1B : Western blot analysis showing upregulation of Kir4.1 protein in membrane fraction of habenula of cLH (FIG. 1A ) and LPS-induced depression rat models (FIG. 1B ). Tubulin is used as loading control.FIGS. 1C and 1D : I-V plot and bar graph showing Ba2+-sensitive current in cLH rats and their wild type controls at the age of P60-90 (FIG. 1C ) and P30 (FIG. 1D ).FIGS. 1E and 1F : Age-dependent learned helpless (FIG. 1E ) and forced swim (FIG. 1F ) phenotypes of cLH rats. Low number of lever press and high immobility time indicate depressive-like phenotype in P90 cLH rats. Data are means±SEM. Numbers in the bars indicate the number of animals used. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; n.s., not significant. -
FIGS. 2A-2D show that Kir4.1 is expressed on astrocytic processes tightly wrapping around neuronal soma.FIG. 2A : Immunohistochemistry signals of Kir4.1 envelope neuronal soma as indicated by white arrows.FIG. 2B : The pan-soma Kir4.1 signals remain intact in LHb of Kir4.1-floxed mice injected with AAV2/1-CaMKII-EGFP-Cre, but are eliminated when injected with AAV2/5-GFAP-EGFP-Cre, (GFAP: human astrocyte-specific GFAP promoter, gfaABC1D).FIG. 2C : Immunogold electron microscopy of Kir4.1. Red arrows indicate gold signals surrounding a neuronal soma.FIG. 2D : I-V plots of the Ba2+ sensitive Kir4.1 current recorded in LHb astrocytes and neurons, with representative traces shown in up-left and statistic bar graph of current recorded when cells are held at −120 mV shown in up-right. Data are means±SEM. ****P<0.0001; n.s., not significant. -
FIGS. 3A-3B show that Kir4.1 is expressed in astrocytic processes of LHb and astrocytic soma of hippocampus.FIGS. 3A and 3B : Kir4.1 co-immunostaining with neuronal marker (NeuN) or astrocytic marker (S100b and GFAP) in LHb (FIG. 3A ) or hippocampus (FIG. 3B ). Bottom two panels are staining with the same kir4.1 antibody pre-incubated with the antigen peptide, demonstrating Kir4.1 antibody. -
FIGS. 4A-4K show that extracellular potassium is highly correlated with the activity pattern and tightly control by astrocytic kir4.1.FIGS. 4A-4C : Changes of neuronal RMPs caused by BaCl2 (100 μM) in different neuronal types.FIGS. 4D-4E : Correlation between BaCl2-sensitive membrane potential and tonic firing frequency (FIG. 4D ), inner burst firing frequency (FIG. 4E ) and burst total spike frequency.FIGS. 4G-4H : Representative trace (FIG. 4G ) and bar graph (FIG. 4H ) shows BaCl2 effect onto bursting neurons.FIG. 4I : Example of a whole-cell patch recording showing LHb neuron spontaneous activity transformed from tonic- to burst-firing mode when Kout is switched from normal (2.75 mM) to half (1.4 mM).FIGS. 4J and 4K : Lowering Kout to half decreases neuronal RMPs (FIG. 4J ) and increases the bursting population in neurons (FIG. 4K ). *P<0.05, **P<0.01, ***P<0.001, compared with the control group; n.s., not significant. -
FIGS. 5A-5I show that overexpression of astrocytic kir4.1 increases neuronal bursts in LHb and causes depressive-like phenotypes.FIG. 5A : Schematics of AAV vectors engineered to overexpress a control construct and Kir4.1 under GFAP.FIG. 5B : Illustration of bilateral viral injection of AAV-GFAP-Kir4.1 in mouse LHb (stained with antibody against GFP and Hoechst).FIG. 5C : Experimental paradigm for electrophysiology and behavioral testing.FIGS. 5D-5F : Astrocytic overexpression of Kir4.1 decreases RMPs of both astrocytes (FIG. 5D ) and neurons (FIG. 5E ) and increases the bursting population in neurons (FIG. 5F ).FIG. 5G : Histogram of inter-spike intervals (ISI, ms) distribution. The ISIs of LHb neurons in astrocytic Kir4.1-overexpressed mice exhibited a clear bimodal distribution with an extra sharp and condensed cluster of high frequency events centred around 40 ms, indicating a significant weight increase of burst firings.FIGS. 5H and 5I : Behavioral effects of expressing various viral constructs in LHb in forced swim test (FST) (FIG. 5H ) and sucrose preference test (SPT) (FIG. 5I ). Data are means±SEM. **P<0.01, ***P<0.001, ****P<0.0001; n.s., not significant. -
FIGS. 6A-6L show that loss of function of Kir4.1 in LHb decreases neuronal bursting and rescues depressive-like phenotypes.FIG. 6A : Schematics of the AAV vector engineered to overexpress shRNA or dominant negative form of Kir4.1. H1, human H1 promoter. CAG: The CMV early enhancer/chicken beta actin promoter.FIG. 6B : Western blot and quantification showing efficient knock-down of Kir4.1 by shRNA in HEK293T cells.FIGS. 6C-6H : Electrophysiological characterization in LHb of AAV-Kir4.1-shRNA and AAV-ctrl-shRNA injected rats. Floating bars for membrane slope conductance calculated from the I/V plots (between −120 and +40 mV).FIG. 6D : Experimental paradigm for behavioral testing of cLH rats infected by virus.FIG. 6E : I-V plots showing a shift of reverse potential from −72 mV to −40 mV in astrocytes infected by AAV-Kir4.1-shRNA.FIGS. 6F and 6G : AAV-Kir4.1-shRNA caused more depolarized RMP in astrocytes (FIG. 6F ) and neurons in the viral infected region (FIG. 6G ).FIG. 6H : AAV-Kir4.1-shRNA abolished neuronal bursting.FIGS. 6I-6L : Behavioral effects of expressing various viral constructs in the LHb of cLH rats in forced swim (FIG. 6I ), learned helpless (FIGS. 6J and 6K ) and sucrose preference (FIG. 6L ) tests. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, n.s., not significant. -
FIG. 7 shows characterization of Kir4.1 loss-of-function constructs. Flag-tagged-Kir4.1 plasmid (pAAV-CMV-betaGlobin-Kir4.1-eGFP-3Flag) was co-transfected with pAAV-vector expressing 6 different shRNAs (see Methods) of Kir4.1 or the negative control (shRNA of luciferase) into HEK293TN cell. Based on the knock-down efficiency as shown in the western blot, Kir4.1-shRNA-5 was chosen for viral package. -
FIGS. 8A-8B show that overexpression of Kir4.1 or Kir4.1-shRNA in LHb does not affect locomotion in open field test.FIG. 8A : Overexpression of Kir4.in LHb does not affect locomotion activities.FIG. 8B : Overexpression of Kir41-shRNA in LHb does not affect locomotion activities. Data are means±SEM. n.s., not significant. -
FIGS. 9A-9C show the nucleotide sequence comparison between human, mouse and rat Kir4.1 mRNAs. -
FIG. 9D shows the amino acid sequence comparison between human, mouse and rat Kir4.1 proteins. -
FIG. 9E shows the sequence alignment results between the target sequence correspond to each of the shRNA No. 1-6 and the human Kir4.1 mRNA sequence. - The nature and benefits of the present disclosure are further described with reference to the following examples, which are intended to illustrate the invention provided herein and not to limit the scope of the present disclosure.
- Animals. Male Wistar rats (12 weeks) and Sprague Dawley rats (3-4 weeks or 12 weeks) were purchased from Shanghai SLAC Laboratory Animal Co. The cLH rats were introduced from Malinow's lab in Cold Spring Harbor of USA, and screened by learned helpless test for breeding as previously described (Schulz et al., 2010). Male cLH rats (3-4 weeks or 12 weeks) were used. Male adult (7-8 weeks of age) C57BL/6 mice (SLAC) were used for virus injection experiments. Animals were group-housed two/cage for rats and four/cage for mice under a 12-h light-dark cycle (light on from 7 a.m. to 7 p.m.). Animals were housed in stable conditions with food and water ad libitum. All animal studies and experimental procedures were approved by the Animal Care and Use Committee of the animal facility at Zhejiang University.
- Virus and Plasmid Construct.
- For knock-out tests, AAV5-gfaABC1D-GFP-CreMut (titer: 4.74×1012 v.g./ml) was ordered and prepared by Taitool Bioscience of China. AAV2/1-CamKII-HI-eGFP-Cre were purchase from University of Pennsylvania Vector core, Upenn, USA (Cat #: AV-1-PV2521). All viral vectors were aliquoted and stored at −80° C. until use.
- For overexpression of Kir4.1 tests, AAV2/5-gfaABC1D-EGFP-Kir4.1 was prepared, for which pZac2.1 gfaABC1D-eGFP-Kir4.1 plasmid (AddGene, Plasmid #52874) and the AAV virus (Taitool Bioscience of China, titer: 9.19×1012 v.g./ml) was used. The package and preparation of the Kir4.1 overexpression viral deliver system was ordered and prepared from Taitool Bioscience of China. A blank control, AAV-GFAP::GFP which expressed GFP but not Kir4.1 was also ordered and prepared from Taitool Bioscience of China.
- For loss-of-function of Kir4.1 tests, a Kir4.1 mutation construct and viral deliver system (namely AAV5-gfaABC1D-dnKir4.1-2A-eGFP, titer: 4.15×1013 v.g./ml) wherein GYG at position 130-132 are mutated to be AAA was ordered and prepared from Taitool Bioscience of China.
- For another loss-of-function of Kir4.1 test, shRNA constructs and viral deliver systems targeting Kir4.1 were ordered from and prepared by Taitool Bioscience of China.
- A total of 6 shRNA sequences were designed by using RNAi designer online software (Invitrogen), which are purported to target the following target sequence in the rat mRNA sequence of rat (as set forth in SEQ ID NO.:7):
-
1) (SEQ ID No. 1) 5′-GGACGACCTTCATTGACAT-3′; 2) (SEQ ID No. 2) 5′-GCTACAAGCTTCTGCTCTTCT-3′; 3) (SEQ ID No. 3) 5′-GCTCTTCTCGCCAACCTTTAC-3′; 4) (SEQ ID No. 4) 5′-CCGGAACCTTCCTTGCAAA-3′; 5) (SEQ ID No. 5) 5′-GCGTAAGAGTCTCCTCATTGG-3′ 6) (SEQ ID No. 6) 5′-GCCCTTAGTGTGCGCATTA-3′. - Six shRNA plasmids were prepared accordingly. In particular, the six shRNA were cloned in a vector named WX231-L (Taitool Bioscience of China, Cat #: WX231) based on the sequences as shown in the following Table 1.
-
TABLE 1 Sequences for shRNA cloning and construction (each sequence has a direction from 5′ end to 3′ end). shRNA Sticky No. end Target seq. Loop Rev seq. PolyT shRNA- TCC GGACGACCTTCATTG TTCAA ATGTCAATGAAGGT TTTTT 1 CC ACAT (SEQ ID No. 1) GAGA CGTCC(SEQ ID No. 9) TCT GGACGACCTTCATTG TCTCT ATGTCAATGAAGGT G AAA ACAT TGAA CGTCC AAA (SEQ ID No. 1) (SEQ ID No. 9) shRNA- TCC GCTACAAGCTTCTGC TTCAA AGAAGAGCAGAAGC TTTTT 2 CC TCTTCT (SEQ ID No. GAGA TTGTAGC(SEQ ID 2) No. 10) TCT GCTACAAGCTTCTGC TCTCT AGAAGAGCAGAAGC G AAA TCTTCT (SEQ ID No. TGAA TTGTAGC(SEQ ID AAA 2) No. 10) shRNA- TCC GCTCTTCTCGCCAAC TTCAA GTAAAGGTTGGCGA TTTTT 3 CC CTTTAC(SEQ ID No. GAGA GAAGAGC(SEQ ID 3) No. 11) TCT GCTCTTCTCGCCAAC TCTCT GTAAAGGTTGGCGA G AAA CTTTAC(SEQ ID No. TGAA GAAGAGC(SEQ ID AAA 3) No. 11) shRNA- TCC GCCGGAACCTTCCTT TTCAA TTTGCAAGGAAGGT TTTTT 4 CC GCAAA (SEQ ID No. GAGA TCCGGC(SEQ ID No. 19)1 20)2 TCT GCCGGAACCTTCCTT TCTCT TTTGCAAGGAAGGT G AAA GCAAA (SEQ ID No. TGAA TCCGGC(SEQ ID No. AAA 19)1 20)2 shRNA- TCC GCGTAAGAGTCTCCT TTCAA CCAATGAGGAGACT TTTTT 5 CC CATTGG (SEQ ID No. GAGA CTTACGC(SEQ ID 5) No. 13) TCT GCGTAAGAGTCTCCT TCTCT CCAATGAGGAGACT G AAA CATTGG (SEQ ID No. TGAA CTTACGC(SEQ ID AAA 5) No. 13) shRNA- TCC GCCCTTAGTGTGCGC TTCAA TAATGCGCACACTA TTTTT 6 CC ATTA (SEQ ID No. 6) GAGA AGGGC(SEQ ID No. 14) TCT GCCCTTAGTGTGCGC TCTCT TAATGCGCACACTA G AAA ATTA (SEQ ID No. 6) TGAA AGGGC(SEQ ID No. AAA 14) Note: 1The sequence as set forth in SEQ ID No. 19 is substantially the sequence as set forth in SEQ ID No. 4 plus an additional “G” at its 5′ end, in order to increase the cloning and/or transcription efficiency; 2The sequence as set forth in SEQ ID No. 20 is the reverse complimentary of the sequence as set forth in SEQ ID No. 19, and the sequence as set forth in SEQ ID No. 20 consists substantially of a sequence (TTTGCAAGGAAGGTTCCGG, as set forth in SEQ ID No. 12), which is substantially the reverse complimentary of the sequence as set forth in SEQ ID No. 4, plus a “C” at its 3′ end. Such a design is purported to increase the cloning and/or transcription efficiency. - The knocking down efficiency was tested by Western blot of Kir4.1 from HEK293TN cells which were co-transfected with Flag-tagged-Kir4.1 plasmid (pAAV-CMV-betaGlobin-Kir4.1-eGFP-3Flag) and each of the six shRNA plasmids. The fifth sequence, 5′-GCGTAAGAGTCTCCTCATTGG-3′, was chosen for use in Kir4.1-shRNA virus package.
- AAV5-H1-Kir4.1-shRNA-CAG-eGFP (titer: 3.04×1013 v.g./ml) and AAV5-H1-Luciferase-shRNA-CAG-eGFP (titer: 1.46×1013 v.g./ml) were ordered and prepared by Taitool Bioscience of China.
- LPS-induced depression model. The LPS-induced depression model was conducted as previously described (Adzic et al., 2015). Adult (3 months) Wistar male rats were used for the experiments. LPS (Sigma, L-2880) dissolved in sterile 0.9% saline was intraperitoneally injected into Wistar rats, at a dosage of 0.5 mg/kg. This dosage was used to stimulate a subclinical infection without inducing obvious inflammation and other apparent impairment in the animals. Saline or LPS was injected between 09:30 and 10:30 a.m. daily for 7 days. The forced swim test was performed 24 hours after the last injection. The habenular tissue was dissected 24 hours after the behavioral test.
- Stereotaxic surgery and virus injection. cLH rats or mice (postnatal 50-60 days) were deeply anesthetized by using 4% pentobarbital and placed in a stereotactic frame (RWD Instruments, China). All measurements were made relative to bregma for virus/implant surgeries (For rats, LHb: AP, −3.7 mm from bregma; ML, ±0.7 mm; DV, −4.1 mm from the brain surface; for mice: AP, −1.72 mm from bregma; ML, ±0.46 mm; DV, −2.62 mm from the brain surface). Virus injection was performed using a mircoinjection needle with a pressure microinjector (Picospritzer III, Parker, USA) delivering virus at a slow rate of 0.1 ul/min. After the injection was completed, two minutes were allowed to pass and leaving it for an additional 10 minutes before the needle was then slowly withdrawn completely. After surgery, mice recovered from anesthesia under a heat pad.
- At least 14 days after injection, mice or rats were used in behavioral or electrophysiological studies. All the injection sites will be checked by immunostaining after the behavioral experiments. Only mice with correct injection site will be counted into the behavioral statistics.
- Immunohistochemistry. Animals were anesthetized using 10% chloral hydrate, and then perfused transcardially with ice-cold PBS (pH 7.4) followed by 4% paraformaldehyde. After overnight post fix in 4% paraformaldehyde solution, brains were cryoprotected in 30% sucrose for 1 day (for mice) or 3 days (for rats). Coronal sections (40 μm) were cut on a microtome (Leica) and collected in PBS and stored at 4° C. for further using. The antibodies used were rabbit anti-Kir4.1 extracellular peptide (1:200, Alomone labs), mouse anti-GFAP (1:500, Sigma), mouse anti-NeuN (1:500, Millipore), mouse anti-S100b (1:500, Sigma), chicken anti-GFP (1:1000, Abcam), Alexa Fluor488 goat anti-rabbit IgG, Alexa Fluor488 goat anti-chicken IgG, Alexa Fluor594 goat anti-mouse IgG (all 1:1000, Invitrogen). Specifically, for Kir4.1 staining, the rabbit anti-Kir4.1extracellular peptide antibody was incubated for 48-72 h and the other primary antibodies were incubated for 36-48 h. For the antibody absorption experiments, the rabbit anti-Kir4.1 extracellular peptide antibody was pre-adsorbed with the Kir4.1 antigen by mixing at the weight ratio of 1:2 for 24 h. Slices were counterstained with Hoechst in the final incubation step to check the injection site. Fluorescent image acquisition was performed with an Olympus Fluoview FV1000 confocal microscope and a Nikon A1confocal microscope.
- Western Blot. The habenular membrane fraction and whole protein was extracted as previously described11. Animals were anesthetized using 10% chloral hydrate, and habenular tissue was quickly dissected from the brain and homogenized in lysis buffer (320 mM sucrose, 4 mM HEPES pH7.4, 1 mM MgCl2 and 0.5 mM CaCl2, 5 mM NaF, 1 mM Na3VO4, EDTA-free, Protease Inhibitor cocktail tablets (Roche)) on ice. The lysis buffer used for extracting the total protein of HEK293TN cell contained 50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS and Protease Inhibitor cocktail tablets (Roche). After protein concentration measurement by BCA assay, 10˜20 μg proteins for each lane was separated on a 10% SDS-PAGE gel and transferred for western blot analysis. Anti-Kir4.1 (1:1000, Alomone labs), anti-GFAP (1:1000, Sigma) and anti-tubulin (1:5000, Bio-Rad) antibodies were used. High sensitive ECL reagent was used (GE Healthcare). All the bands were analyzed with Quantity one or Image J.
- LHb brain slice preparation. Rats (P25-30 or P60-90) and mice (P90) were anesthetized with isoflurane and 10% chloral hydrate, and then perfused with 20 ml ice-cold ACSF (oxygenated with 95% O2+5% CO2) containing (mM): 125 NaCl, 2.5 KCl, 25 NaHCO3, 1.25 NaH2PO4, 1 MgCl2, 2.5 CaCl2) and 25 Glucose, with 1 mM pyruvate added. The brain was removed as quickly as possible after decapitation and put into chilled and oxygenated ACSF. Coronal slices containing habenular (350 μm- and 300 μm-thickness for rats and mice, respectively) were sectioned in cold ACSF by a Leica2000 vibratome and then transferred to ASCF at 32° C. for incubation and recovery. ACSF was continuously gassed with 95% 02 and 5% CO2. Slices were allowed to recover for at least 1 hour before recording.
- In vitro electrophysiological recording. For LHb neuron recordings, currents were measured under whole-cell patch clamp using pipettes with a typical resistance of 4-6 MS/filled with internal solution containing (mM) 105 K-Gluconate, 30 KCl, 4 Mg-ATP, 0.3 Na-GTP, 0.3 EGTA, 10 HEPES and 10 Na-phosphocreatine, with pH set to 7.35. The external ACSF solution contained (in mM) 125 NaCl, 2.5 KCl, 25 NaHCO3, 1.25 NaH2PO4, 1 MgCl2, 2.5 CaCl2) and 25 Glucose. Cells were visualized with infrared optics on an upright microscope (BX51WI, Olympus). A MultiClamp 700B amplifier and pCLAMP10 software were used for electrophysiology (Axon Instruments). The series resistance and capacitance was compensated automatically after stable Giga seal were formed. The spontaneous neuronal activity was recorded under current-clamp (I=0 pA) for consecutive 60 s. RMP was determined during the silent period of the neuronal spontaneous activity.
- To test TTX (1 μM, Sigma) and BaCl2 (100 μM, Sigma) effect onto neuronal RMP, baselines of RMP were recorded for at least for 3 min. Drug were then perfused, the arriving of the drug was precisely indicated with a bubble that pre-added before the transition from normal ACSF to drug added ACSF. TTX acts on LHb neuron as quickly as several minutes while BaCl2 takes more 10 min to affect neuronal RMP. The drug effect of TTX and BaCl2 onto neuronal RMP at the time point of 5 min and 15 min were then tested respectively.
- Astrocytic patch and Kir4.1 current isolation. Astrocytes were distinguished from neuron by their small (5-10 μm) oval shaped somata and by electrophysiological features: a hyperpolarized RMP and a low input resistance, a linear I-V relationship and an absence of action potentials in response to increased injection currents. BaCl2 (100 μM, Sigma) were applied to isolate Kir4.1 current which is subtracted from the IV curve recorded from −120 mV to 0 mV.
- Learned helpless test (LHT). Male juvenile (P30) or adult (P90) cLH rats were tested in a lever-pressing task to evaluate the learned helpless (LH) phenotype11. A cue-light-illuminated lever in the shock chamber was presented, which can terminate the shock when rats pressed the lever. 15 escapable shocks (0.8 mA) were delivered with a 24 s inter-shock interval were given. Each shock lasted up to 60 s unless the rat pressed the lever to terminate the shock. Out of the 15 trials, rats which failed to press the lever for more than 10 trials were defined as “learned helplessness” (LH), and rats with less than 5 failures were defined as “non-learned helplessness” (NLH).
- Forced swim test (FST). Animals were individually placed in a cylinder (12 cm diameter, 25 cm height for mice; 20 cm diameter, 50 cm height for rats) of water (23-25° C.) and swam for 6 min under normal light. Water depth was set to prevent animals from touching the bottom by tails and hind limbs. Animal behaviors were videotaped from the side. The immobility time during the last 4 min test was counted offline by an observer blind of the animal treatments. Immobility was defined as time when animals remained floating or motionless with only movements necessary for keeping balance in the water. For rats, an additional pre-test was conducted 24 h before the test, during which rats were individually placed in a cylinder of water with conditions described above for 15 min.
- Sucrose preference test (SPT). Animals were single housed and habituated with two bottles of water for 2 days, followed by two bottles of 2% sucrose for 2 days. Animals were then water deprived for 24 h and then exposed to one bottle of 2% sucrose and one bottle of water for 2 h in the dark phase. Bottle positions were switched after 1 h. Total consumption of each fluid was measured and sucrose preference was defined as the ratio of sucrose consumption divided by total consumptions of water and sucrose.
- Statistical analyses. Required sample sizes were estimated based on our past experience performing similar experiments. Animals were randomly assigned to treatment groups. Analyses were performed in a manner blinded to treatment assignments in all behavioral experiments. Statistical analyses were performed using GraphPad Prism software v6. By pre-established criteria, values were excluded from the analyses if the viral injection or drug delivering sites were out of LHb. All statistical tests were two-tailed, and significance was assigned at P<0.05. Normality and equal variances between group samples were assessed using the D'Agostino & Pearson omnibus normality test and Brown-Forsythe tests respectively. When normality and equal variance between sample groups was achieved, one-way ANOVAs (followed by Bonferroni's multiple comparisons test), or t test were used. Where normality or equal variance of samples failed, Mann-Whitney U test were performed. Linear regression test, Chi-square test was used in appropriate situations.
- Western blot analysis confirmed that Kir4.1 had a significant increase (1.75-fold) in the membrane protein extraction of cLH habenulae (
FIG. 1A ). To test whether Kir4.1 upregulation is universal in depression, an additional depression animal model, the LPS (lipopolysaccharide)-induced depression was used. One week of LPS injection (0.5 mg/kg, i.p.) in 3-month-old Wistar rats was sufficient to cause strong depressive-like phenotype in the forced swim test (FST). The Kir4.1 level was also significantly increased in the LPS-depression rats (FIG. 1B , 1.87-fold). - Kir4.1 is a principal component of the glial Kir channel and is largely responsible for mediating the K+ conductance and setting the RMP of astrocytes. To confirm that Kir4.1 function is indeed upregulated, whole-cell patch clamp was performed onto the astrocytes in brain slices made from the LHb of cLH or SD rats. Astrocytes were distinguished from neurons by their small (5-10 μM) oval shaped somata and electrophysiological features including a relatively hyperpolarized RMP (−74±1 mV), a low input resistance Rin (47±6 MΩ), a linear I-V relationship and an absence of action potentials in response to depolarizing current injections (
FIG. 1C ). Ba2+ (BaCl2, 100 μM) was then bath applied, which selectively blocks Kir channels at sub-mM concentrations, to isolate Kir4.1 current. The Ba2+-sensitive currents displayed a reversal potential close to Ek (−90 mV) (FIGS. 1E and 1F ), indicating it represents the K+ conductance. It was found that Ba2+-sensitive currents in LHb astrocytes were almost doubled in cLH rats, compared with SD controls, at the age of P60-90 (FIG. 1C ). Interestingly, the increase of Kir4.1 current was not obvious at P30 (FIG. 1D ). At this age, cLH rats did not yet show depressive-like phenotypes in both learned helpless test (LHT,FIG. 1E ) and the forced swim test (FST,FIG. 1F ), suggesting that level of Kir4.1 overexpression correlated with the developmental onset of the depressive-like symptoms. - As an inwardly rectifying K+ channel, Kir4.1 has been strongly implicated in buffering excess extracellular K+ in tripartite synapses. Conventional model of K+ buffering suggests Kir4.1 to be highly expressed in astrocytic endfeet surrounding synapses. Surprisingly, with immunohistochemistry co-labeling, Kir4.1 staining in LHb appeared to overlap with the neuronal marker NeuN at low magnification (20×,
FIG. 3A ), although in the same brain slice Kir4.1 staining patterns in hippocampus were typical astrocytic-looking (FIG. 3B ). However, higher magnification imaging with single layer scanning (0.76 μm per layer) revealed that Kir4.1 staining enveloped NeuN signals (FIG. 2A ). To confirm that Kir4.1 indeed locates within astrocytes but not neurons in LHb, kir4.1 was separately knocked out in either neurons or astrocytes by injecting AAV virus expressing the cre recombinase under either the neuronal promoter CaMKII or glial promoter GFAP (gfaABC1D) into Kir4.1-floxed mice by using AAV5-gfaABC1D-GFP-CreMut (titer: 4.74×1012 v.g./ml), which was provided as mentioned in Example 1. The neural-surrounding staining of Kir4.1 remained intact with neuronal knock-out, but was completely eliminated with astrocytic knock-out (FIG. 2B ). Electron microscopy imaging revealed that Kir4.1-positive gold particles were distributed encircling the membrane of neuronal cell bodies (FIG. 2C ), as well as in the synapses. Consistently, whole-cell-patch recordings showed that Ba2+-sensitive currents are absent in neurons but abundant in astrocytes in LHb (FIG. 2D ). Together these results suggest that Kir4.1 is mainly expressed in astrocytic processes tightly wrapping around neuronal soma and synapses in LHb. - How does an astrocytic potassium channel regulate RMP and burst firing of the LHb neuron? The inventors hypothesize that within the highly confined extracellular space between neuronal soma and Kir4.1-positive astrocytic processes (
FIGS. 2A-2D ), the majority of constantly-released K+ from intrinsically active LHb neurons is quickly cleared by astrocytes through a Kir4.1-dependent mechanism. Accordingly, the Inventors predicted that blockade of Kir4.1 should compromise K+ spatial buffering, resulting in increased extracellular K+(Kout), and according to Nernst Equation, depolarized neuronal RMPs. Consistent with this prediction, blocking Kir4.1 with BaCl2 depolarized LHb RMPs of tonic and burst-firing, but not silent neurons, after about 10 min bath perfusion of BaCl2 (FIGS. 4A-4C ). The amount of changes in RMP positively correlated with the original firing rates of neurons (FIGS. 4D-4F ), indicating the more active the neuron is, the larger contribution the K+ buffering to its RMP. Consequent to the RMP change, perfusion of BaCl2 caused a dramatic increase of firing frequency until the neuron reached a sustained plateau of a tetanus response and stopped firing (FIGS. 4G-4H ). - To assess a causal relationship between Kout and firing mode, current-clamp recordings of LHb neurons were made while lowering Kout from 2.75 mM to 1.4 mM (
FIG. 4I ). This led to lowered neuronal RMP by 13.7+/−0.5 mV (FIG. 4J ) and a direct shift of originally tonic-firing neurons into bursting mode (FIG. 4I ). Consequently, percentage of bursting neurons was increased from 8% to 23% (FIG. 4K ). In summary, by increasing astrocytic Kir4.1 expression or decreasing the extracellular K+ concentration, it was able to phenocopy in WT animals several key neuronal properties observed in the LHb of animal models of depression, namely hyperpolarized RMPs and enhanced bursts. These results indicate that enhanced capacity of extracellular K+ clearance due to Kir4.1 overexpression may underlie the neuronal hyperpolarization required for burst initiation. - To test the effects of Kir4.1 upregulation in LHb, a Kir4.1 overexpression system AAV2/5-gfaABC1D-EGFP-Kir4.1 (namely “AAV-Kir4.1” or “AAV-GFAP::Kir4.1”) was prepared and assayed, which uses adeno-associated viruses of the 2/5 serotype (AAV2/5) that preferentially target astrocytes as the vector, together with the human GFAP (gfaABC1D) promoter for the expression. The Kir4.1 overexpression system GFP-tagged Kir4.1 channels (AAV-GFAP::Kir4.1) was prepared as described in Example 1, while AAV-GFAP::GFP which expressed GFP but not Kir4.1 was used as a control (
FIG. 5A ). - 14 days after bilateral injection in the LHb at P50, AAV2/5-mediated viral transduction led to Kir4.1 and GFP expression in astrocytes throughout the LHb (
FIG. 5B ). Whole-cell recordings were made from either astrocytes or neurons surrounding the viral-transfected astrocytes in coronal LHb slices. The RMPs of both astrocytes and neurons were more hyperpolarized (FIGS. 5D and 5E ) and the percentage of bursting neurons were significantly higher (FIG. 5F ) in mice infected with AAV-GFAP::Kir4.1 than with AAV-GFAP::GFP. - Depressive-like phenotypes were then assayed on and it was found that mice with AAV-GFAP::Kir4.1 infection in the LHb displayed severe depressive-like behaviors (
FIGS. 5C-5I ), including increased immobile duration and decreased latency to immobility in FST (FIG. 5H ), and decreased sucrose preference in the sucrose preference test (SPT,FIG. 5I ). - Next, to determine whether loss-of-function of Kir4.1 in LHb may reverse depressive phenotypes, two strategies were tried by using AAV2/5 viral vectors to express either a short hairpin RNA (shRNA) to knock down the level of Kir4.1, or a dominant negative construct to block its function in the LHb of cLH rats (
FIG. 6A ). - Six shRNAs specifically targeting the Kir4.1 transcript in cell culture were tested. The results showed that the knock-off efficient of these 6 shRNAs were: Kir4.1-shRNA-1>Kir4.1-shRNA-4/Kir4.1-shRNA-5>Kir4.1-shRNA-2>Kir4.1-shRNA-6>Kir4.1-shRNA-3. The one with most efficient knock-down efficiency was chosen for viral package (
FIG. 6B andFIG. 7 ). After viral expression of this shRNA under the H1 promoter in the LHb of cLH rats (FIG. 6C ), its effect was examined on glial and neural electrophysiological properties. In astrocytes infected with the AAV-Kir4.1-shRNA vector, it was found that a dramatic change of I-V relation (FIG. 6E ) and a 32 mV depolarization compared with neighboring non-infected astrocytes and 41 mV depolarization compared with ctrl-shRNA-GFP+ astrocytes (FIG. 6F ). In neurons infected with the AAV-Kir4.1-shRNA vector, the RMPs did not differ from neighboring non-infected neurons (because neurons do not express Kir4.1 endogenously,FIG. 6G ). However, RMPs of LHb neurons from AAV-Kir4.1-shRNA-infected brain slices were overall more depolarized than RMPs of those from AAV-luciferase-shRNA-infected rats (−43±2 mV vs. −53±2.7 Mv,FIG. 6G ), suggesting that knock-down of Kir4.1 in astrocytes had a global impact on RMPs of neighboring neurons. Most importantly, bursting activity in LHb of cLH rats were completely eliminated by AAV-Kir4.1-shRNA viral infection (from 29% to 0%,FIG. 6H ). - Behaviorally, infection of AAV-Kir4.1-shRNA had a pronounced effect on rescuing the depressive-like phenotypes of cLH rats in three depression paradigms: reducing the immobility time and increasing latency to immobility in FST (
FIG. 6I ), increasing bar pressing number in the LHT (FIGS. 6J and 6K ), and increasing the sucrose preference score in SPT (FIG. 6L ). - To avoid an off-target effect of shRNA, a dominant-negative form of Kir4.1, dnKir4.1, containing a GYG to AAA point mutation at the channel pore which blocks K+ channels was also tested. The preparation of the Kir4.1 mutation construct and viral deliver system (namely AAV-dnKir4.1, or AAV5-gfaABC1D-dnKir4.1-2A-eGFP) was prepared as described in Example 1. Infection of AAV-dnKir4.1 caused similarly strong anti-depression effects in cLH rats (
FIGS. 6I-6L ): reducing the immobility time and increasing latency to immobility in FST (FIG. 6I ), increasing bar pressing number in the LHT (FIGS. 6J and 6K ), and increasing the sucrose preference score in SPT (FIG. 6L ). - The experiments as described above, which have largely been performed using rodent animal models (i.e. rat and mouse), have established a crucial role of the inward rectifier potassium (Kir) channel Kir4.1 (or KCNJ10) that is specifically expressed in the astroglial tissues or astrocytes in the lateral habenula (LHb) in causing the depression-like phenotype, at least in these rodent animal models. LHb Kir4.1 has been demonstrated to be able to regulate neuronal resting membrane potential (RMP) and bursting, and importantly, has been shown to be significantly upregulated in depression. The gain-of-function and the loss-of-function manipulations of Kir4.1 in the rodent animals have been shown to respectively cause and rescue depression, indicating that astroglial Kir4.1 is both necessary and sufficient for causing depression. Thus these above results point to Kir4.1 in the LHb as a potential target for treating clinical depression.
- In order to estimate whether, and to what extent, the above study results can be translated into other higher species like humans, a series of sequence conservation studies is performed.
- Firstly, a comparative study among the Kir4.1 mRNA sequences of rat (as set forth by SEQ ID NO. 7, see NCBI Reference Sequence: NM_031602.2), mouse (as set forth by SEQ ID NO. 15, see NCBI Reference Sequence: NM_001039484.1), and human (as set forth by SEQ ID NO. 17, see NCBI Reference Sequence: NM_002241.5) has shown that 86.7% of the nucleotide residues are identical, and 98.9% of the nucleotide residues show at least a consensus across the three species (
FIGS. 9A-9C ). - Secondly, a comparative study among the Kir4.1 amino acid sequences of rat (as set forth by SEQ ID NO. 8, see NCBI Reference Sequence: NP_113790.2, which corresponds to NM_031602.2), mouse (as set forth by SEQ ID NO. 16, see NCBI Reference Sequence: NP_001034573.1, which corresponds to NM_001039484.1), and human (as set forth by SEQ ID NO. 18, see NCBI Reference Sequence: NP_002232.2, which corresponds to NM_002241.5) has shown that 97.9% of the amino acid residues are identical, and 99.7% of the amino acid residues show at least a consensus across the three species (
FIG. 9D ). - Given the extremely high conservation between human Kir4.1 and rodent Kir4.1 in terms of the mRNA sequences (having 98.9% consensus positions) and the protein sequences (having 99.7% consensus positions), Kir4.1 shall play a similarly crucial role in the lateral habenula (LHb) in the pathogenesis and maintenance of depression.
- A survey over the above mentioned Kir4.1-targeting shRNAs (shRNA NOS. 1-6) has shown that each of their corresponding target sequences on the rat Kir4.1 mRNA sequence (i.e. as set forth in SEQ ID NO. 7), which are respectively set forth in SEQ ID NOS. 1-6, also represents a relatively high level of homology in the alignment (see
FIG. 9E ) with the human mRNA sequence of Kir4.1 (i.e. as set forth in SEQ ID NO. 17), with the 21-base target sequence for shRNA-2 (as set forth in SEQ ID NO. 2) being 100% identical, only one-base difference for both the 19-base target sequences of shRNA-1 and shRNA-6 (as set forth in SEQ ID NOS. 1 and 6 respectively), three-base difference for the 21-base target sequence of shRNA-5 (as set forth in SEQ ID NO. 5), and four-base difference for the 21-base target sequences of shRNA-3 and for the 19-base target sequences of shRNA-4 (as set forth in SEQ ID NOS. 3 and 4, respectively). As such, among the 6 shRNAs that have been utilized for suppressing expression of rat Kir4.1, at least the shRNA-2, likely the shRNA-1, 6 and 5, and potentially shRNA-4 as well, can be utilized to suppress the expression of human Kir4.1, and thus can serve as a component of a pharmaceutical agent capable of inhibiting the activity of the astroglial potassium channel Kir4.1 in a human subject with depression to suppress the bursting activity of neurons in a lateral habenula of the subject for treatment of the disease. - Regarding the dominant negative mutant form of Kir4.1 protein (i.e. dnKir4.1), containing a GYG-to-AAA point mutation corresponding to position 130-132 of the amino acid sequence of wild-type Kir4.1 protein of rat Kir4.1 (as set forth in SEQ ID NO. 8), since the three-amino-acid sequence is strictly conserved within the 88-amino acid context region at positions 101-188 of all of the human, mouse and rat Kir4.1 proteins (as respectively set forth in SEQ ID NOS. 18, 16 and 8, see
FIG. 9D ), tissue-specific overexpression of such a mutant protein in the LHb of a human subject is expected to also interfere with the normal functionality of Kir4.1 in a dominant negative manner, and consequently, the bursting activity in the LHb of the human subject can be eliminated, thereby realizing an effective treatment of depression in the human subject. As such, the dnKir4.1 can similarly be used as a pharmaceutical agent capable of inhibiting the activity of the astroglial potassium channel Kir4.1 in a human subject with depression to suppress the bursting activity of neurons in a lateral habenula of the subject for treatment of the disease. - Notably also, the vectors that have been utilized for the astrocyte-specific expression of shRNAs or dnKir4.1 in the rat studies as described above, such as AAV-GFAP, and esp. the AAV2/5 shall also be able to realize a similar astrocyte-specific expression of shRNAs (e.g. shRNA-2) and dnKir4.1 to be able to exert the therapeutic effects.
- The present disclosure for the first time and unexpectedly find that burst in neurons of the lateral habenula has an important role in the cause of depression, and identify key factors affecting the burst in the lateral habenula, including that the activation of NMDA receptors is the sufficient and necessary condition for inducing burst in the lateral habenula, and that burst in the lateral habenula need the participation of neuron membrane hyperpolarization and T-type low voltage activate calcium channel. Particularly, the present disclosure for the first time and unexpectedly find that it is the burst instead of whole neuron firing or neuron discharges that contribute to the cause of depression. The inventors provide a method and medicament for diagnosing and treating (inhibiting) depression by inhibiting burst in lateral habenula, especially method and medicament for rapidly treating (inhibiting) depression.
- Unless otherwise indicated, the practice of the present disclosure will employ common technologies of organic chemistry, polymer chemistry, biotechnology, and the like. It is apparently that in addition to the above description and examples than as specifically described, the present disclosure can also be achieved in other ways. Other aspects within the scope of the disclosure and improvement of the present disclosure will be apparent to the ordinary skilled in the art. According to the teachings of the present disclosure, many modifications and variations are possible, and therefore it is within the scope of the present disclosure.
- Unless otherwise indicated herein, the temperature unit “degrees” refers to Celsius degrees, namely ° C.
- All references that have been referred to in the present application are incorporated by reference in their entirety for all purposes.
-
- 1. Adzic et al. Behav. Brain Res. 291, 2015.
- 2. Banasr et al., Biological psychiatry 64, 863-870, 2008.
- 3. Cotter et al., Archives of general psychiatry 58, 545-553, 2001.
- 4. Coyle et al., Archives of
general psychiatry 57, 90-93, 2000. - 5. Cui et al. Nature 554, 323-327.
- 6. Czeh et al., the journal of the European College of
Neuropsychopharmacology 23, 171-185, 2013. - 7. Hamilton et al., Frontiers in
neuroenergetics 2, 2010. - 8. Hiroshi et al., Physiological Reviews 90, 291-366, 2010.
- 9. Kharade et al., Molecular Pharmacology 94, 926-937, 2018.
- 10. Ohno et al., Brain Research 1178, 44-51, 2007.
- 11. Rajkowska et al., CNS & neurological
disorders drug targets 6, 219-233, 2007. - 12. Schulz et al., Neurobiol Learn Mem 93, 291, 2010.
- 13. Wang et al., Psychophamacology 183, 490-499, 2006.
Claims (20)
1. A method for treating depression in a subject, wherein the depression is characterized by abnormal burst firings of neurons in a lateral habenula (LHb) of the subject, the method comprising:
administering to the subject a therapeutically effective amount of a pharmaceutical agent capable of interfering with a function or inhibiting an activity of Kir4.1 in the LHb of the subject such that the abnormal burst firing of the neurons in the LHb of the subject is suppressed, wherein the Kir4.1 has at least 95% sequence identity to SEQ ID NO. 18.
2. The method of claim 1 , wherein the pharmaceutical agent comprises a recombinant vector configured to express in astrocytes in the LHb of the subject polypeptide molecules capable of inhibiting the function or the activity of the Kir4.1.
3. The method of claim 2 , wherein the polypeptide molecules comprise a mutant Kir4.1 protein capable of interfering with the function of the Kir4.1 in a dominant negative manner, wherein the mutant Kir4.1 protein comprises a sequence alteration at a channel core region of the Kir4.1.
4. The method of claim 3 , wherein the sequence alteration is at a GYG segment corresponding to positions 130-132 of the Kir4.1 as set forth in any one of SEQ ID NOS. 8, 16 or 18.
5. The method of claim 4 , wherein the sequence alteration comprises a GYG-to-AAA point mutation.
6. The method of claim 2 , wherein the polypeptide molecules comprise an anti-Kir4.1 antibody.
7. The method of claim 2 , wherein the recombinant vector is a recombinant viral vector capable of preferentially or specifically targeting the astrocytes of the subject.
8. The method of claim 7 , wherein the recombinant vector is based on an adeno-associated virus (AAV) of 2/5 serotype (AAV2/5).
9. The method of claim 7 , wherein the administering to the subject a therapeutically effective amount of a pharmaceutical agent comprises:
obtaining virus particles carrying the recombinant viral vector; and
administering the virus particles to the subject.
10. The method of claim 9 , wherein the administering the virus particles to the subject is through an injection or an inhalation.
11. The method of claim 1 , wherein the pharmaceutical agent comprises a small molecule agent capable of inhibiting the activity of the Kir4.1 in the LHb of the subject.
12. The method of claim 11 , wherein the small molecule agent comprises a selective serotonin reuptake inhibitor (S SRI) capable of inhibiting the activity of the Kir4.1 in the LHb of the subject.
13. The method of claim 12 , wherein the SSRI is selected from a group consisting of buspirone, mianserin, fluoxetine, sertraline, and fluvoxamine.
14. The method of claim 11 , wherein the small molecule agent comprises a tricyclic antidepressant (TCA) capable of inhibiting the activity of the Kir4.1 in the LHb of the subject.
15. The method of claim 14 , wherein the TCA is selected from a group consisting of nortriptyline, amitriptyline, desipramine, and imipramine.
16. The method of claim 11 , wherein the small molecule agent comprises a selective Kir4.1 inhibitor.
17. The method of claim 16 , wherein the selective Kir4.1 inhibitor comprises VU0134992.
18. The method of claim 1 , wherein the pharmaceutical agent comprises a recombinant vector configured to express in astrocytes in the LHb of the subject express a short hairpin RNA (shRNA) molecule, wherein the shRNA molecule comprises two complementary sequences, and one of the two complementary sequences has a nucleotide sequence that is substantially identical to a sequence as set forth in any one of SEQ ID NOS. 1-4 and 6.
19. The method of claim 1 , wherein the administering to the subject a therapeutically effective amount of a pharmaceutical agent comprises:
administering the pharmaceutical agent to the subject in a systemic manner.
20. The method of claim 1 , wherein the administering to the subject a therapeutically effective amount of a pharmaceutical agent comprises:
administering the pharmaceutical agent locally to the LHb of the subject.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/717,140 US20230050684A1 (en) | 2017-05-09 | 2022-04-11 | Use of potassium channel inhibitor for treating depression |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710322245 | 2017-05-09 | ||
CN201710322245.X | 2017-05-09 | ||
PCT/CN2018/086021 WO2018205927A1 (en) | 2017-05-09 | 2018-05-08 | Use of potassium ion channel inhibitor for treatment of depression and pharmaceutical composition |
US16/679,197 US11326168B2 (en) | 2017-05-09 | 2019-11-09 | Use of potassium channel inhibitor for treating depression |
US17/717,140 US20230050684A1 (en) | 2017-05-09 | 2022-04-11 | Use of potassium channel inhibitor for treating depression |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/679,197 Division US11326168B2 (en) | 2017-05-09 | 2019-11-09 | Use of potassium channel inhibitor for treating depression |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230050684A1 true US20230050684A1 (en) | 2023-02-16 |
Family
ID=64104328
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/679,197 Active US11326168B2 (en) | 2017-05-09 | 2019-11-09 | Use of potassium channel inhibitor for treating depression |
US17/717,140 Pending US20230050684A1 (en) | 2017-05-09 | 2022-04-11 | Use of potassium channel inhibitor for treating depression |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/679,197 Active US11326168B2 (en) | 2017-05-09 | 2019-11-09 | Use of potassium channel inhibitor for treating depression |
Country Status (4)
Country | Link |
---|---|
US (2) | US11326168B2 (en) |
EP (1) | EP3622958B1 (en) |
CN (2) | CN115006534B (en) |
WO (1) | WO2018205927A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114788868B (en) * | 2021-01-15 | 2024-06-21 | 北京钟楣科技有限公司 | Application of gene inhibitor in preparation of depression treatment drugs |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11471428B2 (en) * | 2017-05-09 | 2022-10-18 | Zhejiang University | Method and pharmaceutical composition for treating depression |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005054848A2 (en) * | 2003-11-25 | 2005-06-16 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled inwardly rectifying potassium channel (girk2) |
ATE486606T1 (en) * | 2004-09-18 | 2010-11-15 | Univ Maryland | THERAPEUTIC AGENTS FOR TARGETING THE NCCA ATP CHANNEL AND METHOD OF USE THEREOF |
EP2530088A1 (en) * | 2011-05-30 | 2012-12-05 | Klinikum rechts der Isar der Technischen Universität München | Means and methods for diagnosing and treating multiple sclerosis |
EP2887806B1 (en) * | 2012-07-20 | 2019-11-13 | University Of Rochester | Method of treating and preventing brain impairment using na+-k+ -2ci- cotransporter isoform 1 inhibitors |
CN104338135B (en) * | 2013-08-09 | 2018-08-24 | 中国科学院上海生命科学研究院 | The regulatory factor of depression and its application |
-
2018
- 2018-05-08 WO PCT/CN2018/086021 patent/WO2018205927A1/en unknown
- 2018-05-08 EP EP18798117.0A patent/EP3622958B1/en active Active
- 2018-05-08 CN CN202210060456.1A patent/CN115006534B/en active Active
- 2018-05-08 CN CN201810432839.0A patent/CN108853505B/en active Active
-
2019
- 2019-11-09 US US16/679,197 patent/US11326168B2/en active Active
-
2022
- 2022-04-11 US US17/717,140 patent/US20230050684A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11471428B2 (en) * | 2017-05-09 | 2022-10-18 | Zhejiang University | Method and pharmaceutical composition for treating depression |
Non-Patent Citations (4)
Title |
---|
Cui et al. "Astroglial Kir4.1 in the Lateral Habenula Drives Neuronal Bursts in Depression". Nature. 2018 Feb 14; 554(7692):323-327. (Year: 2018) * |
Kharade et al. "Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992". Molecular Pharmacology. 2018 Aug; 94(2):926-937. Published Online June 12, 2018. (Year: 2018) * |
Vollmayr et al. "Rats with Congenital Learned Helplessness Respond Less to Sucrose but Show No Deficits in Activity and Learning". Behav Brain Res. 2004 Apr 2; 150(1-2):217-221. (Year: 2004) * |
Yang et al. "Ketamine Blocks Bursting in the Lateral Habenula to Rapidly Relieve Depression". Nature. 2018 Feb 14; 554(7692):317-322. (Abstract Only) (Year: 2018) * |
Also Published As
Publication number | Publication date |
---|---|
US20200149051A1 (en) | 2020-05-14 |
US11326168B2 (en) | 2022-05-10 |
CN115006534A (en) | 2022-09-06 |
CN108853505B (en) | 2022-02-25 |
CN115006534B (en) | 2023-11-21 |
CN108853505A (en) | 2018-11-23 |
EP3622958A1 (en) | 2020-03-18 |
WO2018205927A1 (en) | 2018-11-15 |
EP3622958B1 (en) | 2024-03-20 |
EP3622958A4 (en) | 2021-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Arrant et al. | Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis | |
Dell'Orco et al. | Neuronal atrophy early in degenerative ataxia is a compensatory mechanism to regulate membrane excitability | |
US20200308589A1 (en) | Dynamin 2 inhibitor for the treatment of centronuclear myopathies | |
KR102359994B1 (en) | Application of hexokinase 2 specific inhibitors for acute central nervous system injury diseases | |
CN116064423A (en) | HSV vectors for delivery of NT3 and treatment of CIPN | |
AU2013286815B2 (en) | Methods for inhibiting neuron apoptosis and necrosis | |
Muhia et al. | Molecular and behavioral changes associated with adult hippocampus-specific SynGAP1 knockout | |
WO2015018375A1 (en) | Depression regulatory factor and applications thereof | |
US20230046305A1 (en) | Peptides and other agents for treating pain and increasing pain sensitivity | |
US20230050684A1 (en) | Use of potassium channel inhibitor for treating depression | |
JP6879738B2 (en) | snoRNA, composition, and use | |
US20190111111A1 (en) | Treatment of Cerebral Cavernous Malformations | |
WO2017201425A1 (en) | Anabolic enhancers for ameliorating neurodegeneration | |
US11241478B2 (en) | Adenovirus-associated viral vectors for expressing variants of tetratricopeptide repeat (TPR)-containing Rab8b interacting (TRIP8b) protein in neurons and uses thereof for treating major depressive disorder (MDD) | |
JP6653054B2 (en) | Composition for treating brain injury disease targeting TIM-3 and screening method thereof | |
JP2018177658A (en) | Treatment of castration resistant prostate cancer | |
Sweeney | eScholarship@ UMMS | |
US20230203497A1 (en) | Dynamin 2 inhibitor for the treatment of centronuclear myopathies | |
US20220265607A1 (en) | Methods and compositions for unsilencing imprinted genes | |
Zhang et al. | CA1i pyramidal neurons mediate the role of NMDA receptor subunit GluN3A in depressive behavior and D-serine anti-depression | |
Kharouf et al. | The hyperpolarization-activated cyclic nucleotide-gated 4 channel as a potential anti-seizure | |
US20180327778A1 (en) | Animal models for brain inflammation and white matter degeneration | |
Sweeney et al. | Let us know how access to this document benefits you. | |
WO2019232368A1 (en) | TARGETING P18 FOR mTOR-RELATED DISORDERS | |
EP3880209A1 (en) | Compositions and methods for regulating inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |